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ABSTRACT
CCAAT/enhancer binding proteins (C/EBPs) are modular
transcription factors that play important roles in energy metabolism. For
example, C/EBP transcription factors are important regulators of the
expression of phosphoenolpyruvate carboxykinase (PEPCK), a key
regulatory enzyme in gluconeogenesis in the liver. In support of this,
C/EBP knockout analysis and antisense methodologies have uncovered a
role for C/EBPa in mediating the cAMP responsiveness of the PEPCK
gene promoter. The work in this thesis is dedicated to defining the
regions within C/EBPa and C/EBPP that mediate the constitutive and
PKA-inducible activity towards the PEPCK promoter.
Examination of the regions of C/EBPa and C/EBPP previously
characterized to mediate a robust PKA-inducible response identified three
conserved regions (CRs). Deletion analysis, in conjunction with GAL4
methodology and dominant negative transfection analysis, showed that
CR2 (amino acids (aa) 61-70) was critical for mediating the PKA-inducible
activity when C/EBPa occupied the distal sites on the PEPCK promoter.
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However, CR3 (aa 96-106) and amino acids 6-50 of C/EBPa were found to
be important for mediating the PKA-inducible response when it bound to
the cAMP Response Element site (CRE). In contrast, the CRs within
C/EBP~ did not appear to contribute to the PKA-inducible activity
regardless of where it bound to the PEPCK promoter.
GST-pull down analysis indicated that aa 6-50 and CR3, but not
CR2, were required for C/EBPa to physically interact with TATA-binding
protein (TBP) and Transcription Factor II B (TFIIB). This protein-protein
analysis, in conjunction with transient transfection analysis, suggested
that the domains within C/EBPa that mediate the constitutive and PKA-
inducible activities vary depending on which cis-element it occupies on
the PEPCK promoter. For example, when C/EBPa binds to the CRE site,
amino acids 6-50 and CR3 may mediate the constitutive and PKA-
inducible activity through a mechanism that may involve physical
interaction with TBP and TFIIB. However, when C/EBPa binds to the
distal promoter region, CR2 may mediate the PKA-inducible response by
interacting with different proteins, possibly a co-activator. The data
suggest that the precise location of a transcription factor on a promoter
may influence which domains within the protein are employed to mediate
transactivation.
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1. INTRODUCTION AND OVERVIEW
Phosphoenolpyruvate carboxykinase (PEPCK) gene is a paradigm
for the study of transcription regulation. The PEPCK enzyme has no
known allosteric regulators, it is not post-translation~llymodified, the
gene/protein has tissue specific and developmentally specific patterns of
expression and its expression is regulated almost entirely at the level of
transcription initiation. Because PEPCK is a key regulator of
gluconeogenesis, its gene promoter is composed of a complex array of cis-
elements that allow its rate of expression to be responsive to a variety of
hormones.
Studies performed on the PEPCK gene promoter have revealed that
its cyclic AMP (cAMP) response unit consists of three binding sites for
CCAAT/enhancer binding protein a (C/EBPa) and/or C/EBP~, as well as
an Activator Protein-1 (AP-1) site, and a cAMP Response Element (CRE)
site that can bind C/EBPa, C/EBP~ or cAMP Response Element Binding
Protein (CREB) (Park et al., 1990; Roesler et al., 1994, 1998; Roesler, 2000;
Short et al., 1986). C/EBPa and C/EBP~ are liver enriched transcription
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factors that participate in the protein kinase A (PKA)-inducible response
of PEPCK and a number of metabolically important genes. The goal of
this thesis is to determine if these isoforms share any regions of homology
between their transactivation domains and, if so, to determine whether the
conserved regions mediate the PKA-inducible activity when they bind to
the PEPCK promoter. As the results section of this th€3is will show, the
homologous domains within C/EBPu, but not C/EBPP, are critical for
mediating the PKA-inducible response on the PEPCK promoter. These
data suggest that although these isoforms share regions of conserved
amino acids, these regions may not share a conserved function. Also, this
thesis will indicate that promoter environment may influence which
domains within C/EBPa mediate the constitutive and PKA-inducible
activities on the PEPCK promoter.
To gain a greater understanding for how this research project is
designed, the literature review is outlined as follows: Section 2.1 describes
the basic concepts of transcriptional regulation and this section expands
into the study of hormonal regulation of a gene promoter in greater detail.
Section 2.2 evaluates the hormonal regulation of the PEPCK gene
promoter. Section 2.3 describes the C/EBP protein family in detail in
terms of their biological and metabolic roles, and their structure and
2
function. Section 2.4 describes the transactivational activity of C/EBPa
and C/EBPp. Finally, section 2.5 outlines the specific objectives of this
thesis.
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2. REVIEW OF THE LITERATURE
2.1 Overview of Transcription Regulation
Eukaryotic gene expression is a two-stage process that is
functionally and physically separated in the cell. Transcription, the
synthesis of messenger RNA (mRNA) from the deoxyribonucleic acid
(DNA) template, is localized to the nucleus whereas translation, the
synthesis of proteins from the mRNA template, is localized to the
cytoplasm. Transcriptional regulation is central to tissue specific gene
expression and cellular response to a specific stimulus (Latchman, 1997).
The major point of regulation of gene expression is transcription initiation
although mRNA degradahon and post-transcriptional modifications do
contribute to the control of gene expression. Most eukaryotic genes are
expressed at a constitutive level until their rate of transcription is induced
in response to a stimulus (Barberis and Gaudreau, 1998).
The regulatory structure of a eukaryotic gene consists of a proximal
upstream promoter and distant enhancer sequences (Beyersmann, 2000).
An ordered assembly of general transcription factors combine to form the
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preinitiation complex, including Transcription Factor Class II Gene F
(TFIIF) which escorts RNA polymerase II to the promoter to initiate
transcription (Latchman, 1997; Smale, 2001). Enhancers are found at
variable distances from the proximal promoter, upstream or downstream
of the initiation start site and they often mediate an effect independent of
orientation. An enhancer consists of cis-elements or specific sites on the
DNA template that can be bound by specific and often inducible trans-
activation factors (Figure 2.1). The ability of these proteins to induce or
repress gene expression may be altered by post-translational modification
and the presence or absence of accessory factors (Beyersmann, 2000,
Chang and Jaehning, 1997).
A protein is constitutively expressed when the general
transcription factors form the pre-initiation complex and recruit RNA
polymerase II to the promoter. Hormonal induction of transcription
requires the correct assembly of the preinitiation complex as well as the
correct assembly of inducible transcription factors tethered to sites within
the enhancer region. The number and identity of cis-elements on a
promoter varies from gene to gene and the identity of transcription factors
that bind to each cis-element may vary depending on the regulatory
5
Transcription Factors
Figure 2.1: Schematic diagram of a hypothetical TATA-containing
promoter. This diagram id2ntifies general transcription factors (including
the TATA binding protein (TBP) and its associated TATA-binding protein
associated factors (TAFs), various transcription factors and co-activators.
The general transcription factors and RNA polymerase II associate to form
the preinitiation complex. Upstream transcription factors (A, B and C)
bind to DNA cis-elements (1, 2 and 3). These transcription factors may be
phosphorylated and associate with various co-activators (I, II, III) which
may act as a bridge between the enhancer region and the general
transcription factors.
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properties of the gene and which hormones are present (for reviews see
Lucas and Granner, 1992 and Roesler and Park, 1998).
Transcription factors are often modular proteins with a distinct
domain for tethering the protein to a specific cis-element on the DNA and
a transactivation domain for mediating the stimulatory or inhibitory effect
on gene expression (Latchmann, 1997). While not all transcription factors
bind to consensus sites on the DNA, this is generally the case. The most
common DNA binding domain motifs are the helix-loop-helix motif, the
basic region-leucine zipper domain (bZIP), and the zinc finger domain
(Beyersmann, 2000; Latchman, 1997; Mitchell and Tijan, 1989).
Transactivation domains are characterized as glutamine rich, acidic amino
acid rich or proline rich and these domains mediate the protein-protein
interaction between transcription factors, co-activators and/or members of
the preinitiation complex (Beyersmann 2000; Chen, 1999; Mitchell and
Tijan, 1989). The actions of DNA binding domains and transactivation
domains are often physically and functionally distinct from each other,
which means that the DNA binding domain of a trans~ription factor can
be replaced with an alternate DNA binding domain, often with no
discernible effect on the activity of the transactivation domain.
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2.1.1 Hormone Response Units
The presence of hormones can lead to the alteration of the
expression of countless genes, especially genes that code for proteins that
form the rate-limiting enzymes of metabolic pathways (Lucas and
Granner, 1992). It has recently been elucidated that for a hormone to
affect gene transcription, the gene promoter may be composed of several
cis-elements that synergize to mediate a robust response. These cis-
elements are collectively referred to as a hormone response unit (HRU)
(reviewed in Roesler and Park, 1998). Each HRU is composed of a
hormone response element which mediates a measurable response to the
hormone in isolation but it cannot account for the full effect of the
hormone on gene expression. The HRU may be composed of one or more
accessory elements which bind accessory factors. Accessory factors are
transcription factors which fail to mediate a mea~urable hormonal
response independently but they serve to amplify the response of the
transcription factor that binds the hormone response element. An
accessory factor may serve to stabilize protein-DNA interactions at the
hormone response element, it may stabilize protein-protein interactions
between the hormone res?onse element and the general transcription
factors and it may also assist in recruitment of co-activators to the
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promoter (Roesler and Park, 1998). Each hormone that acts upon a
specific gene promoter may have its own HRU which may include unique
and/or shared cis-elements. Multiple transcription fact0rs may bind to a
single site within the HRU and the unique combination of transcription
factors allow for a "fine-tuned" response of the promoter to the hormone.
Essentially, a gene can exist in altered states of hormonal responsiveness
depending on the particular combination of transcription factors that
occupy specific cis-elementr- within the HRU (Roesler, 2000).
2.2 Overview of PEPCK Gene Expression
The PEPCK enzyme is a key regulator of gluconeogenesis in the
liver, and gluconeogenesis and ammoniagenesis in renal cells (for reviews
see Hanson and Patel, 1994 and Hanson and Reshef, 1997). However,
PEPCK is also expressed in non-gluconeogenic tissues such as adipose
tissue, lactating mammary glands and the small intestine (Anderson, 1970;
Ballard, et al., 1967; Feldman and Hirst, 1978; Lobato, et al., 1985; Zimmer
and Magnuson, 1990). In non-gluconeogenic tissues, PEPCK mediates
limited glyceroneogenesis during starvation by producing 3-
phosphoglycerate which is used to convert free fatty acids into di- or tri-
acylglycerols. PEPCK catalyzes the conversion of oxaloacetate to
9
phosphoenolpyruvate and carbon dioxide (C02) using GTP as a substrate
and releasing GDP as a byproduct.
Oxaloacetate + GTP ...~t----.- Phosphoenolpyruvate + GDP + C02
PEPCK is the first committed step in gluconeogenesis in liver and
kidney cells and its expression is induced during the perinatal period
concomitant ,vith an increased need for self-sufficient gluconeogenesis
(Hanson and Reshef, 1997; Rognstad, et al., 1979). There are cytosolic and
mitochondrial isoforms of PEPCK which are encoded by separate genes
but the mitochondrial isoform is not induced by any known stimuli and
will therefore not be discussed in this thesis. The expression of cytosolic
PEPCK is altered in the liver by dietary and hormonal stimuli. Its
expression is up-regulated during starvation, after prolonged exercise, in
the presence of increased levels of glucocorticoids and in the diabetic
state; however, its expression is reduced in response to insulin and after a
prolonged, high carbohydrate diet (Alleyne and Scullard, 1969; Friedman,
1994; Hanson and Patel, 1984; Lamers, et al., 1982; Sasaki, et al., 1984,
Tilghman, et al., 1974).
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2.2.1 Transcriptional Regulation of the PEPCK Gene in Liver
Although PEPCK is a key regulatory enzyme in gluconeogenesis, it
is not post-translationally modified, it has no known allosteric modifiers,
and its expression is regulated almost entirely at the level of transcription.
However, there is limited control of PEPCK's mRNA stability. Its mRNA
half-life is increased in response to fasting and it is extended from
approximately 30 minutes to nearly four hours in the presence of cAMP
(Hod, et al., 1988; Nachaliel, et al., 1993; Nelson, et al., 1980). By increasing
PEPCK's mRNA half-life, PEPCK expression can be induced during times
of insufficient glucose uptakE:.
PEPCK expression is induced in the presence of cAMP,
glucocorticoids, retinoic acid and thyroid hormone and its expression is
inhibited by insulin (Granner, et al., 1983; Lamers, et al., 1982; Loose, et al.,
1985; Lucas, et al., 1991). By utilizing multiple HRUs to mediate these
responses, the PEPCK promoter has increased control over its response to
hormones and tissue specific and developmental cues. The effects of
glucagon (via cAMP) and the cAMP response unit will be discussed in
detail in the following section.
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2.2.1.1 The cAMP Response Unit
It is only recently that the mechanism whereby cAMP activates
gene expression in eukaryotes has expanded from the limited view that a
CRE mediates the response to the much more complex view that a HRU
mediates the cAMP response. The CRE is a palindromic sequence with
the consensus sequence 5'TGACGTCA3' and it is the binding site for the
transcription factor CREB (Hoeffler, et al., 1988; Montminy and Bilezikjian,
1987; Shaywitz and Green1:'erg, 1999). Initially, it was thought that CREB
alone mediated the cAMP response. CREB is phosphorylated on a single
serine residue by PKA and this phosphorylation /1activates" CREB
(Shaywitz and Greenberg, 1999). Upon phosphorylation, CREB can bind
CREB Binding Protein, a co-activator that induces gene expression by
contacting several members of the preinitiation complex and by altering
the promoter environment with its intrinsic histone acetylase activity
(Chrivia, et al., 1993, Lee, et al., 2001). This limited CRE model has several
failings. It does not account for the tissue specificity that some cAMP
responsive genes display because CREB and CREB binding protein are
ubiquitously expressed. Furthermore, it does not explain how a CRE site
may fail to mp.diate a strong cAMP response in some genes. The PEPCK
gene is a perfect example to demonstrate these limitations. PEPCK is
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robustly responsive to cAMP in the liver but it mediates a limited cAMP
response in the kidney (Lamers, et al., 1982; Meisner, et aL, 1985).
Transfection analysis with a PEPCK promoter that is truncated after the
CRE site is only weakly responsive in the presence of PKA compared to
the PEPCK promoter that extends out to nucleotide -490 (Roelser, et al.,
1993). Obviously, ubiquitiously expressed CREB cannot account for
PEPCK's tissue specific PKA-inducible response; other proteins upstream
of the CRE are required to mediate the PKA-inducible effect. These
observations led to the discovery and elucidation of a cAMP response unit
(CRU) within the PEPCK promoter that is responsible for mediating this
hormonal response.
In an attempt to identify transcription factors that may help
mediate the PKA-inducible response, DNase I footprinting of the PEPCK
promoter was performed using nuclear extracts from rat liver, spleen,
kidney and brain tissues (Roesler, et al., 1989). In conjunction with a
footprint at the nonconsenesus CRE site within the PEPCK promoter, a
distinct liver-specific footprinting pattern was identified between -230
and -320 bp. As expected, the CRE site could be occupied by recombinant
CREB but competition with an oligonucleotide which contains aCRE
sequence was noticed to compete with the protein at the eRE and an
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upstream region. Transient transfection analysis identified that a robust
response to PKA was only realized if the upstream region was included
with the CRE on the promoter (Roesler, et al., 1993). The importance of the
upstream site for determining the tissue-specific response was elucidated
when it was identified that the liver specific transcription factor, C/EBPa
bound to three specific sites within the PEPCK promoter (Park, et al., 1990;
Roesler, et al., 1996). Extensive analysis of the various cis-elements on the
PEPCK promoter identified an upstream region (now termed the Liver
Specific Region (LSR» which consists of an AP-1 binding site and three
C/EBP binding sites. Together with the CRE site, these cis-elements
constitute the CRU (Figure 2.2) (Roesler, et al., 1994). There appears to be
no specific architectural requirement for these five cis-elements but the
three C/EBP binding sites, the AP-1 site and the CRE must all be present
for a robust PKA-inducible response to be realized (Liu, et al., 1991;
Roesler, et al., 1994).
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Figure 2.2: Schematic of the cAMP response unit of the PEPCK promoter. The
CRU of the PEPCK promoter is composed of five cis-elements; three CIEBP
binding sites and an AP-l binding site within the Liver Specific Region (-330/-
225 bp) and a CRE at position -85 bp from the initiation start site.
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Using multiple experimental techniques including recombinant
protein expression, transient transfection analysis and mutation analysis
(i.e. converting the nonconsensus CRE site within the PEPCK promoter to
a consensus C/EBP site or CRE site,) it was determined that the CRE
element in the PEPCK promoter can be occupied by C/EBPu, C/EBP~ and
CREB and binding of any of these three transcription factors (within the
context of the CRU) results in a strong PKA-inducible response (Liu, et al.,
1991; Park, et ai., 1990; 1993; Roesler, et al., 1989; 1995; 1998; Wilson, et. al.,
submitted). Previously, it was believed that C/EBP~ bound to this site to
mediate the glucocorticoid response but binding to the CRE inhibited the
cAMP response (Roesler, et al., 1998; Yamada, et al., 1999). Further
transient transfection analysis showed that a truncated version of C/EBP~
could mediate a strong PKA-inducible response when it bound to the CRE
(Wilson, et. al., submitted)
Using GAL4 methodology, a robust PKA-inducible response could
be observed when C/EBPu or truncated C/EBP~was tethered to the distal
sites on the PEPCK promoter (Park, et al., 1999; Roesler, et al., 1996).
Briefly, this methodology entails removing the endogenous DNA binding
domain of a specific transcription factor and replacing it with the DNA
binding domain of the yeast transcription factor, GAL4. This recombinant
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protein was co-expressed in the presence of a permissive PEPCK promoter
which had specific sites within the CRU replaced with one or more GAL4
site. It was discovered that either C/EBPu or C/EBPB could potentially
occupy the three sites within the LSR to mediate a vigorous PKA-
inducible response irrespective of which of the three proteins occupied the
CRE (Park, et al., 1999; Roesler, et al., 1996). A limitation of the GAL4
methodology is that it only indicates a protein's potential to mediate a
hormonal response on a reporter gene but it does not address the effect of
each protein on the endogenous promoter in vivo (Fry and Farnham, 1999).
Crosson and Roesler, (2000) addressed these limitations by inhibiting the
expression of specific C/EBP isoforms using antisense methodology and
studying the effect on the cAMP responsiveness of the PEPCK promoter.
Using H4IIE cells, a liver cell line which expresses PEPCK and responds to
hormones in a manner analogous to hepatocytes, they identified that
C/EBPu, but not C/EBPB, is absolutely required to mediate the cAMP
response on the PEPCK promoter (Crosson and Roesler, 2000).
How each transcription factor competes for binding to the distinct
sites within the CRU is not fully understood. It is speculated that the
relative abundance of each transcription factor may lead to increased
competition for sites on the DNA. Because of the high degree of amino
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acid similarity shared between the bZIP domains of C/EBPa and C/EBPP,
the possibility of C/EBPa/p heterodimers occupying sites in the CRU must
also be considered.
2.3 The CCAAT/Enhancer-Binding Protein Family of Transcription
Factors
C/EBPa was purified from rat liver nuclear extracts and
characterized as a heat-stahle, DNA binding protein (Graves, et al., 1986;
Johnson, et al., 1987). Upon discovery of this protein, it became evident
that C/EBPa marked a new class of transcription factors that interact with
their DNA targets via a basic region-leucine zipper (bZIP) region. This
DNA binding protein recognizes the DNA sequence 5'ATIGCGCAAT3'
but it can bind cis-elements that vary considerably from this consensus
sequence (Agre, et al., 1989; Osada, et al., 1996). Eight isoforms from six
genes compose the C/EBP transcription factor family. All family members
share significant structural similarities in the bZIP domain although they
diverge in their tissue specificity, transactivational activity and
developmental expression patterns.
Many researchers have cloned the C/EBPP gene from several
animal species leading to different nomenclature and confusion in the
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literature. For the sake of clarity, C/EBP~ will be used to represent all the
animal species unless otherwise indicated.
2.3.1 Biological Roles of C/EBP Isoforms
C/EBP transcription factors are critical for normal cellular
differentiation, and developmental and tissue specific gene expression
(Lekstrom-Himes and Xanthopoulos, 1998). C/EBPa is an intronless gene
that is expressed at high levels in the liver, lung, white adipose tissue,
brown adipose tissue and the placenta with its expression being the
highest in the liver and adipose tissue (Birkenmeir, et al., 1989). C/EBPa
plays a significant role in mediating the expression of metabolically
important genes in the liver, in fetal lung development and in initiating
hepatocyte cell cycle arrest (Birkenmeir, et al., 1989; Darlington, 1999;
Flodby, et al., 1996). Darlington and colleagues have investigated the role
of C/EBPa in the acute phase response using C/EBPa knockout mice.
Northern blot analysis indicated that an inflammatory stimulus failed to
induce the acute phase response in C/EBPa knockout IPice, and that mice
without the C/EBPa gene displayed an early block in the maturation of
granulocytes (Zhang, et al., 1997). This study is one of the first to indicate
that C/EBPa has a role in the acute phase response.
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Constitutive expression of C/EBP~ is highest in the liver, intestine,
adipose tissue and lung (Cao, et al., 1991). C/EBP~ was originally
identified as a master regulator of the acute phase response (Akira, et al.,
1990). Like C/EBPu, C/EBP~ also lacks introns. Akira and colleagues
identified C/EBP~ as a nuclear factor that can occupy the interleukin-1
element on the interleukin-6 promoter and induce its expression (Akira, et
al., 1990). Further analysis indicated that C/EBP~ can induce the
expression of a number of genes in the liver such as tumor necrosis factor,
interleukin-8, and granulocyte colony-stimulating factor, genes that are
vital for the acute-phase reaction, inflammation and hematopoiesis (Akira,
et al., 1990). C/EBP~ knockout mice have altered T-helper cells and
humoral immunity, they are more susceptible to skin lesions, they have
elevated interleukin-6 in their blood and they developed splenomegaly
and lymphoadenopathy (Screpanti, et al., 1995; Tanaka, et al., 1995).
Clearly, C/EBP~ plays a major role in regulating the immune response.
After preadipocyte cells have been induced to differentiate into
adipose cells, there is a significant, albeit transient, increase in the
expression of C/EBP~ and C/EBP8 which may initiate adipogenesis by
inducing the expression of C/EBPu (Cao, et al., 1991). Ectopic expression
of C/EBP~ promotes adipogenesis in pre-adipocytes and fibroblast cell
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lines and knockout models of C/EBP~ and C/EBP8 result in pre-adipocytes
that fail to differentiate despite the presence of the appropriate stimuli
(Tanaka, et al., 1997; Wu, et al., 1995). Studies show that C/EBP~ also plays
a role in epithelial cell proliferation, mammary gland differentiation and
C/EBP~ knockout mice females are sterile (Robinson, et al., 1998; Stemeck
et al., 1997).
C/EBP8 is an intronless gene which is expressed in intestine,
adipose tissue and lung, and its expression is stimulated in all tissues after
lipopolysaccharide stimulation (Cao, et al., 1991; Yin, et al., 1996). C/EBP8
and C/EBP~ are expressed in the early stages of adipocyte differentiation
and they have a role in inducing the expression of C/EBPa and other
adipocyte marker genes (Lane, et al., 1999; Tanaka, et al., 1997). C/EBPa, ~
and 8 are emerging as regulators of the cAMP response in a number of
genes revealing the importance of this class of transcription factors in
regulating hormonal responsiveness (Wilson and Roesler, 2002).
C/EBPy is a 16 kD protein which is ubiquitously expressed with its
highest level of expression in progenitor cells. This protein can
heterodimerize with other family members; however, because it lacks a
transactivation domain, dimerization with other family members creates
inactive heterodimers. (Cooper, et al., 1995).
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The C/EBPf: gene consists of two introns and five in-frame
translation initiation sites. The protein is expressed primarily in myeloid
and lymphoid cells and this gene can be transcribed into four mRNA
species (Chumakov, et al., 1997). These mRNA isoforms are translated to
produce proteins with identical leucine zipper domains but different
amounts of transactivation domain (Tang and KoeHler, 2001).
C/EBPl; (also known as growth arrest and DNA damage inducible
gene (gadd53», is a ubiquitously expressed protein which readily
heterodimerizes with other C/EBP isoforms. Dimerization creates inactive
heterodimers due to the presence of two proline residues within the DNA
.binding region of C/EBPl;. These proline residues make it impossible to
bind DNA, which results in C/EBPl; functioning as a dominant negative
inhibitor of C/EBP transcriptional activity (Ron and Habener, 1992).
2.3.1.1 Metabolic Roles of C/EBPa
In 1989, McKnight and colleagues posed the question, "Is
CCAAT/enhancer-binding protein a central regulator of energy
metabolism?" based on the observation that its highest levels of
expression was found in tissues such as liver, adipose and lung, which are
organs that control energy metabolism and/or actively metabolize lipids
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(Birkenmeier, et al., 1989, McKnight, et al., 1989). The work by Darlington
and colleagues has been instrumental in defining C/EBPa as a regulator of
adipose tissue development (Darlington, et al., 1998; Wang, et al., 1995).
They used homologous recombination and cross-breeding experiments to
create mice with a deletion of the C/EBPa gene (C/EBPa-/-) (Wang, et al.,
1995). At birth, these mice had no gross abnormalities. Their blood
glucose levels were normal, their organs appeared normal, their weight
was normal and the C/EBPa-/- mice could not be distinguished from their
littermates. However, several hours after birth, the C/EBPa-/- mice
became increasingly lethargic and most died within 8 hours. Blood
glucose levels taken 5-8 hours post-partum showed a significant drop
compared to the homozygous normal and heterozygous littermates.
These profoundly hypoglycemic mice could be temporarily rescued if
they were injected with a glucose solution every 7 hours after birth.
Pathology showed that, unlike the controllittermates, the C/EBPa
-/- mice had very little liver glycogen prenatally and no liver glycogen
postnatally. These mutant mice had significantly reduced lipid droplets in
their adipose tissue and Northern analysis showed a significantly reduced
expression of uncoupling protein in brown adipose tissue (Wang, et al.,
1995). The C/EBPa-/- mice had significantly reduced hepatic mRNA
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levels of serum albumin, glycogen synthase, PEPCK and glucose-6-
phosphatase relative to control mice in the perinatal period and they had
immature lungs. It was observed, however, that after 32 hours, the
mRNA levels of PEPCK and glycogen synthase recovered suggesting that
another C/EBP isoform may be partially compensating for the loss of
C/EBPa.
Because the C/EBPa knockout mice had a <10/0 survival rate after
the perinatal period, Darlington and colleagues designed a variant of the
C/EBPa-/- mice which expressed C/EBPa in hepatocyte tissue exclusively
(Linhart, et al., 2001). These C/EBPa -/- mice were designed with the
region coding for the C/EBPa protein under the direct transcriptional
control of the serum albumin enhancer region and proximal promoter, a
gene which is expressed exclusively in the liver (albuminaPj C/EBPu-j-
mice). Northern blot analysis confirmed that C/EBPa was expressed in
liver cells but not in any other tissues and this new knockout model had a
3-fold better survival rate than the original C/EBPa-/- mice. The mRNA
expression of PEPCK, glycogen synthase and bilirubin UDP-
glucuronosyltransferase were normal in the albuminap/ C/EBPu-/- mice,
however, these mice showed a selective absence of white adipose tissue.
Lipid accumulation in brown adipose tissue was delayed but by day 7, it
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was readily detectable and had minimal biochemical alterations.
Mammary gland fat tissue was morphologically normal.
Lee and colleagues also recognized the limitations of the first
C/EBPa-/- model which only allowed the study of C/EBPa expression in
the neonate (Lee, et al., 1997a). To gain greater insight into the role of
C/EBPa in the adult mouse, they constructed a conditional knockout allele
of the C/EBPa gene using the Cre/LoxP recombinase system to study the
effects of altered C/EBPa expression specifically in the liver of the adult
mouse (Lee, et al., 1997a). These mice were phenotypically normal
compared to their controllittermates until Cre recombinase was delivered
to the hepatocytes via infusion of a recombinant adenovirus. Studies
showed that, upon infection, more than 800k of the C/EBPa gene was
deleted in the liver and the expression of C/EBPa protein was reduced by
90%. These conditional knockout mice had significantly reduced bilirubin
UDP-glucuronosyltransferase expression in the liver which led to the mice
developing severe jaundice. Similar to the perinatal knockout mice, the
expression of PEPCK and glycogen synthase was significantly reduced, as
was factor IX. These data suggest that not only is C/EBPa important in
the normal expression of PEPCK and glycogen synthase in the neonate, it
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is important for maintaining the expression of these enzymes in the adult
liver.
Adipogenesis is controlled by a complex array of transcription
factors like C/EBPa, p, () and peroxisome proliferator activated protein y
which are expressed at different stages of the differentiation process
(Darlington, et aI., 1995; 1998). C/EBPa inhibits cellular proliferation and
increases the expression of adipose marker genes which leads to the
adipocyte phenotype (Darlington, et aI., 1995; 1998; Lane, et aI., 1999).
Many experiments emphasize that although C/EBPa is expressed
relatively late in the differentiation process, C/EBPa is a master regulator
of adipocyte differentiation. When C/EBPa was over-expressed in 3T3-L1
preadipocyte cells, the differentiation process was initiated despite the
lack of any hormonal signal (Lin and Lane, 1992). Ectopic expression of
C/EBPa in a preadipocyte cell line not only conferred the adipocyte
phenotype but it also conferred insulin-responsive glucose uptake (El-
Jack, et al., 1999). When C/EBPa antisense mRNA was introduced into the
same cell line, preadipocyte differentiation was inhibited but subsequent
introduction of sense C/EBPa mRNA overcame this inhibition (Lin and
Lane, 1992). 3T3-L1 preadjpocyte cells transfected with the C/EBPa gene
showed inhibited adipoblast growth compared to the control cells but
26
within 5 days the cells developed the adipocyte morphology (Freytag and
Geddes, 1992).
Karagiannides and colleagues (2001) studied the effects of altered
C/EBP protein expression in aging mice. Northern blot analysis indicated
that C/EBPa levels in adipocytes declined with age and over-expression of
C/EBPa into preadipocytes cultured from old rats restored the
differentiated adipocyte morphology and fat cell storage capacity
(Karagiannides, et al., 2001), The overall expression level of C/EBPP did
not alter with age in mice but a truncated C/EBPP isoform did increase in
cultured preadipoctyes and isolated fat cells of aged mice. These data
indicate that alterations in C/EBPa and C/EBPP expression may contribute
to age-related impaired adipogenesis and fat tissue function.
Many adipose specific genes such as the ob gene (which codes for
leptin) and the aP2 gene (which codes for a lipid binding protein) have
consensus sites for C/EBPa in their proximal promoters which suggests
that their expression is under the direct control of C/EBPa (Lane, et al.,
1999; Herrera, et al., 1989; Hollenberg, et al., 1997; Hwang, et a/., 1996). The
promoter region of the C/EBPa gene has a C/EBP binding site which can
be occupied by C/EBPI3 and C/EBP8. Once activated, C/EBPa can
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stimulate its own production to maintain the terminally differentiated
state (Christy, et aI., 1991; Timchenko, et aI., 1995).
2.3.1.2 Metabolic Roles of C/EBPP
C/EBPP was first identified as a key element of interleukin
signaling and induction of a number of acute phase response genes
(Akira, et aI., 1990; Poli, et al., 1990). To study the effects of C/EBPP
deficient mice on interleukin-6 expression, Tanaka and colleagues
generated a null mutant of the C/EBPP gene by gene targeting (Tanaka, et
al., 1995). They observed that C/EBPP-/- mice were prone to infection and
they had induced expression of cytokines but, overall, these mice
appeared phenotypically normal (Tanaka, et aI., 1995). However, Tanaka
and others identified that the Mendelian ratio of mice heterozygous for
the C/EBPP deletion was significantly lower than expected from
inheritance and they suggested that this was due to a number of mice
dying in utero (Screpanti, et aI., 1995; Tanaka, et al., 1995).
Researchers have studied C/EBPP knockout models and a complex
pattern of gene expression has been elucidated. Although there are
multiple phenotypes observed with C/EBPP knockout mice, only the B
phenotype and the A phenotype will be discussed in this thesis. Fifty
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percent of the C/EBP~-/- mice have the B phenotype and these mice die
shortly after birth due to their inability to mobilize glycogen stores and to
express hepatic PEPCK (Croniger, et aI., 1997). Administration of cAMP
results in the mobilization of liver glycogen, induced PEPCK expression
and the normalization of blood-glucose levels (Liu, et aI., 1999). Liu and
colleagues determined that the surviving C/EBP~-/- mice had fasting
hypoglycemia and decreased blood lipids. They determined that C/EBPf3
was not required for the normal induction of PEPCK, glucose-6-
phosphatase or glucokinase in response to hormone stimulation directly
but C/EBP~ was required to ensure the appropriate concentrations of
cAMP which directly effect lipid and glucose homeostasis (Liu, et al.,
1999). This latter observation was confirmed by Croniger, et al., (2001)
who identified that C/EBPf3-/- mice have 50% less hepatic cAMP
compared to control mice due to a decreased concentration of PKA and an
increased concentration of cAMP phosphodiesterases (Croniger, et al.,
1998; 2001).
The C/EBP~-/- A phenotype mice had normal glucose homeostasis
but these mice died after 4-6 months due to problems related with a
severely compromised immune system (Croniger, et aI., 1997; Screpanti, et
aI., 1995; Tanaka, et al., 1995). The A phenotype mice had significantly
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reduced lipid accumulation, the females were sterile, they had difficulty in
maintaining fasting blood glucose homeostasis, and they had altered
epithelial cell proliferation, and mammary gland differe~tiation(Croniger,
et al., 1997; 2001; Liu, et al., 1999; Robinson et al., 1998; Screpanti, et al.,
1995; Sterneck, et al., 1997; Tanaka, et al., 1997). Pathology of these mice
showed that they had high circulating blood levels of interleukin-6, they
had altered T-helper and humoral immunity elevating their susceptibility
to infection (Cao, et al., 1991; Screpanti et al., 1995; Tanaka, et al., 1995).
A fascinating study was undertaken by Chen and colleagues in
which the CreILoxP method was used to replace the entire protein-coding
region of C/EBPa with C/EBP~ within the context of the C/EBPa gene
locus (C/EBPaP/P) (Chen, et al., 2000). C/EBPaP/Pmice were viable, their
gross morphology was normal and they had similar body weight
compared to their wild-type littermates. Unlike the previous knockout
models of C/EBPa, these mice had no liver dysfunction, they had normal
blood glucose and albumin levels and both sexes were fertile (Chen, et al.,
2000; Darlington, et al., 1999; Lee, et al., 1997). Northern blot analysis
identified that the concomitant gain of C/EBPP expression under control
of the C/EBPa gene locus in the C/EBPaP/Pmice did not differ from the
C/EBPa expression patterns of the wild-type litter mates which confirmed
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that the genetic manipulation did not affect gene expression. Also, the
expression level of endogenous C/EBPP in C/EBPa~/~ and wild-type
littermates was unaffected. Northern blot analysis of C/EBPa~/~ mice
showed that the PEPCK mRNA levels and timing of expression was
similar to that of wild-type mice.
A closer examination of the C/EBPa~/~mice indicated that although
these mice had similar body weights compared to their wild-type
littermates, their white adipose tissue was small and yellowish in colour,
unlike the heterozygous and wild-type littermates whose white adipose
tissue was large and white. The lipid accumulation in these mutant mice
was inhibited although the C/EBPa~/j3mice had 60°1<> more brown adipose
tissue than the other littermates. Northern analysis showed that genes
involved in adipogenesis in white adipose tissue of C/EBPa~/~mice were
not affected by the loss of C/EBPa expression; however, the mRNA and
protein levels of leptin and adipsin, both of which are white adipose tissue
marker genes, were significantly reduced in these mice. Unlike the
binding pattern of C/EBPP in hepatocytes, C/EBPP has been shown to bind
to putative distal elements in the PEPCK promoter and transactivate its
expression in adipocytes (Eubank, et al., 2001). C/EBPP can functionally
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replace C/EBPa in the liver but not in adipose tissue when it is expressed
from the C/EBPa gene locus.
2.3.2 Structure/Function Analysis of C/EBPa and C/EBPP
C/EBP proteins are modular transcription factors that are
composed of an N terminal transactivation domain and a carboxy
terminal DNA binding domain (Figure 2.3). C/EBPa and C/EBP~ are
extremely G-C rich, intronless genes with the corresponding amino acids
in their DNA binding domains sharing approximately 71°1<> identity
(Trautwein, et al., 1995). However, the amino acid sequence between their
transactivation domains, the region of the proteins that mediate the
constitutive and inducible transactivation potential of the transcription
factor, are largely unique.
2.3.2.1 The DNA Binding Domain of CIEBP
The bZIP domain of C/EBP proteins consists of a bipartite motif
that is responsible for both dimerization and DNA cis-element recognition
and binding (Landschulz, et al., 1989). The leucine zipper domain is an
approximately 30 amino acid segment of the C/EBP protein that resides
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Figure 2.3: Schematic diagram of C/EBP proteins. The transactivation domain
resides at the N terminus, the leucine zipper resides at the C terminus and the
basic region is immediately N terminus to the leucine zipper motif.
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at the extreme C terminus of the protein. The carboxy terminal region of
C/EBP proteins contains 5 leucines repeated at every seventh amino acid
that corresponds to every two turns of the a-helix if the a-helix over-
twists slightly (Krylov, et al., 1994). Using a helical wheel analysis, the a-
helix displays considerable amphipathy: one side of the helix is composed
of a heptad repeat consisting of hydrophobic amino acids and leucines at
positions 1 and 4 in the repeat, and the other side of the wheel has a
significant number of charged amino acids (6 basic amino acids and 4
acidic amino acids) and uncharged, polar amino acids (Figure 2.4)
(Krylov, et al., 1994). The basic region of the C/EBP protein is composed of
a short stretch of basic amino acids immediately N-terminal to the leucine
zipper domain. These positively charged amino acids contact the
negatively charged DNA strands and distort the DNA 1 to 4° (Avitahl and
Calame, 1994).
a-Helices are stabilized by the amphipathic arrangement of their
amino acid Bide chains that allow the formation of salt bridges
(Landschulz et al., 1988). The hydrophobic face of the a-helix facilitates a
contiguous array of stabilizing interactions with another protein; this
heptad repeat is a feature shared by proteins that dimerize in a coiled-coil
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Figure 2.4: Helical wheel analysis of 28 amino acids of the C/EBP carboxy-
terminus. Standard three letter amino acid nomenclature is utilized. Most
notably, the Leu residues corresponding to residues I, 8, 15 and 22 of the
segments analyzed show a distinctive periodicity. This regular repeat of
Leu residues or "leucine zipper" in conjunction with the hydrophobic
amino acids at position 4, 12, etc. are proposed to act as a dimerization
motif between separate polypeptides with similar leucine repeats,
presumably via hydrophobic interactions.
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motif (Krylov, 1994). The leucine zipper repeat allows proteins within the
same family to interdigitate like a zipper thus stabilizing dimerization.
Upon dimerization, the leucine zipper juxtaposes the basic region
allowing it to contact DNA. Although the leucine zipper is not directly
involved in contacting DNA, mutations within the leucine zipper motif
inhibits dimerization making DNA binding impossible (Landschulz, et al.,
1988).
2.3.2.2 The Transactivation Domains of CIEBPa and C/EBPP
The transactivation domains of inducible transcription factors are
responsible for mediating constitutive and hormone inducible expression
of a target gene. Using deletion analysis, several researchers observed
that the N terminus of C/EBPa is composed of two distinct transactivation
domains that are separated by a putative attenuator domain (Pei and Shih,
1991; Friedman and McKnight, 1990). In studying the effect C/EBPa has
on the expression of the serum albumin gene in hepatoma cells, Nerlov
and Ziff (1994; 1995) gained considerable insight into the constitutive
activity of this transcription factor. Using N terminal and internal
deletion mutants of C/EBPa's transactivation domain in transient
transfection experiments, they identified regions of the protein that were
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Figure 2.5: Schematic of the regions within C/EBPa protein responsible
for mediating its constitutive and PKA-inducible response. The regions
responsible for C/EBPa's constitutive and PKA-inducible activities have
been assigned based on the studies of Nerlov and Ziff, 1994; 1995; Pei and
Shih, 1991; Roesler et al., 1998; and Wilson et al., 2001. The numbers
indicate the amino acid residues on the protein. The domains that
mediate the constitutive activity of C/EBPa are shaded black, while the
PKA-inducible domain is shaded gray. The region within C/EBPa that
mediates protein-protein interactions with TATA binding protein (TBP)
and TATA binding protein associated factor II B (TFIIB) are indicated.
The basic region-leucine zipper DNA-binding motif resides at the
carboxy-terminus of the protein and does not appear to contribute to its
constitutive or PKA-inducible activity.
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critical for mediating the constitutive activity of this protein. They
indicated that C/EBPa has three transactivation elements that work in
conjunction with each other to mediate the constitutive responsiveness of
this protein. Deletion of anyone of these elements did not significantly
alter the basal responsiveness of CjEBPa, suggesting these elements are
functionally redundant. However, deletion of two transactivation
elements in any combination greatly diminished its basal activity. GST-
pull down assays indicated that transactivation elements I and II were
responsible for interactions with TBP and TFIIB, members of the general
transcription apparatus (the regions of which are indicated by arrows in
Figure 2.5), and deletion of these interaction sites abolished the
constitutive activity of the protein. Transactivation element III has a
strong negative regulatory domain and the amino acids responsible for
the constitutive activity were spread throughout this transactivation
element. This region binds chromatin remodeling complexes and it
collaborates with the TBP and TFIIB interaction motifs during
adipogenesis (Pedersen, et al., 2001).
Roesler and colleagues performed deletion analysis on the C
terminus of the transactivation domain of C/EBPa to identify the regions
of the protein responsible for mediating its constitutive and PKA-
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inducible responses. They identified that the PKA-responsive domain of
C/EBPa resides within amino acids 50-124 (Roesler, et al., 1998).
Interestingly, mutations of amino acids 67, 77 and 78 in C/EBPa abolished
the constitutive activity of the protein without affecting its ability to
mediate the PKA response. This latter finding suggested that the
constitutive and PKA-inducible activities of C/EBPa are mediated by
different mechanisms and/or different domains. A major focus of this
thesis is the study of the transactivation domain of C/EBPa and C/EBPP to
discern the domains within these proteins that are responsible for
mediating thejr PKA-inducible response on the PEPCK promoter.
Trautwein and colleagues determined that the transactivation
domain of C/EBPP was composed of an acidic domain in the N terminus
of the protein ranging from amino acids 21-105 and they suggested that
amino acids 85-95 interact with the general transcription factors
(Trautwein, et al., 1995). Williams and colleagues delineated that the
transactivation domain of mouse C/EBPP contains two negative
regulatory regions and three activation domain modules (Williams, et al.,
1991; 1995). These activation domain modules, like the transactivation
elements of C/EBPa, have poor transactivation potential in isolation but
they synergize to mediate a full transactivational response of C/EBPp.
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Studies by Roesler, et al., (1998) indicated that PKA responsiveness
of the PEPCK promoter was inhibited when GAL4-C/EBPf3 was bound to
the CRE site or when C/EBPf3 was over-expressed in the presence of the
endogenous PEPCK promoter. This GAL4-chimera consisted of the amino
acids 8-315 of C/EBPf3 (which includes a portion of the DNA binding
domain) fused to the GAL4 DNA-binding domain. However, Park, et al.,
(1999) showed that a truncated transactivation domain of C/EBPf3 (amino
acids 1-108) fused to a GAL4 DNA binding domain could mediate the
PKA responsiveness of this protein on a permissive PEPCK promoter.
The domain extending from amino acids 109-315 may contain a region
that attenuates the PKA-inducible activity of C/EBPf3 on the PEPCK
promoter.
2.3.2.3 Multiple Translation Products of C/EBPa and C/EBPP
Different isoforms of C/EBPa and C/EBPI3 are generated via
translation initiation at multiple in-frame AUG start c0dons. There are
five isoforms of rat C/EBPa expressed from five in-frame AUG start
codons which result in 42, 40,30, 20 and 14 kD isoforms with the 42 and
30 kD isoforms being expressed to high levels in the liver (Greenbaum, et
al., 1995; Hsieh, et al., 1998). Like C/EBPa, C/EBPf3 can be expressed as
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multiple isoforms from its mRNA. Full length C/EBP~ (38 kD) and LAP
(liver-enriched transcriptional activator protein) (35 kD) encodes the
acidic activation domain as well as the highly conserved bZIP domain
(Trautwein, et al., 1995). A 21 kD isoform, LIP (liver enriched
transcriptional inhibitory protein) and a 14 kD isoform both lack the
region corresponding to the transactivation domain although they retain
the ability to heterodimerize and contact DNA (Descombes and Schibler,
1991; Poli, et al., 1990; Williams, et al., 1995). Because the 21 kD and 14 kD
isoforms lack the region corresponding to the transactivation domain,
these proteins act as dominant negative proteins when they
heterodimerize with other family members (Descombes and Schibler,
1991; Williams, et al., 1995).
By initiating translation from several in-frame AUG start codons,
different isoforms of C/EBPs are generated which have unequal portions
of its transactivation domain. Using H4IIE cells and stable transfection
analysis, Crosson and colleagues observed that while the overall mRNA
level of C/EBPa was decreased in streptozotocin-induced diabetic rat
liver, the 30 kD isoform was much more significantly reduced than the
larger transcript (Crosson, et al., 1997). These data suggest that in the
diabetic rat liver, there is a shift towards the recognition of the first start
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codon of C/EBPa over the second start codon. In other words, expression
of a transcription factor's full-length or truncated transcripts can be
potentially influenced in a hormonal or diseased state that affects the
activity of the protein.
2.3.2.4 Regulation of CIEBPa and CIEBPP DNA Binding by
Phosphorylation
Because the bZIP domains of C/EBPa and C/EBPP share such a
significant degree of homology and they recognize the same cis-elements,
there remains the question of how one isoform is selected to bind specific
cis-elements on a gene promoter over another isoform. Obviously,
increasing the expression level of an isoform and/or the more active
variant of an isoform will allow this isoform a greater competitive
advantage for binding to cis-elements. Studies have been undertaken to
identify potential phosphorylation sites within the bZIP domain of each
isoform to discern if the phosphorylation state of an isoform affects its
ability to bind DNA. The bZIP domain of C/EBPa can be phosphorylated
by Protein kinase C (PKC) on Ser248, Ser277 and Ser299, with the latter site
significantly inhibiting its DNA binding ability in vitro but it is not clear if
these Ser sites can be phosphorylated in vivo (Mahoney et al., 1992).
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However, it is known that the bZIP domain of C/EBPa is not a target for
PKA (Mahoney, et al., 1992).
C/EBP~ can be phosphorylated by PKA and PKC on Ser240, a site
within the basic region of the protein (Chinery, et al., 1997).
Phosphorylation of this site by either kinase abrogates its DNA-binding
ability (Trautwein, et al., 1995). These data offer an explanation of how the
different isoforms may be selected for DNA binding. In the presence of
PKA, the DNA binding domain of C/EBP~ may be phosphorylated,
inhibiting its ability to interact with the cis-element and, by default,
C/EBPa can bind to the cis-element without competition from C/EBP~.
Others, however, have suggested that C/EBP~ is not phosphorylated by
PKA to any great extent in vivo (Wegner, et al., 1992). Phosphorylation of
C/EBP~ on Ser240 also stimulates the nuclear translocation of C/EBP~ from
the cytosol which may aid in the protein's ability to outcompete other
C/EBP isoforms for sites on the promoter (Chinery, et al., 1997; Metz and
Ziff, 1991). Obviously, the role of phosphorylation in affecting the in vivo
DNA binding ability of C/EBPa and C/EBP~ must be much more
extensively studied.
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2.4 Mechanism of CIEBPa and CIEBPP Transactivation Activity
C/EBPs have historically been considered as constitutively acting
factors, unlike other transcription factors whose activities can be regulated
by covalent modification, binding of a specific ligand, etc. in the presence
of hormones. C/EBPa and C/EBP~ have several transactivation domains,
some of which can physically interact with general transcription factors
present in the preinitiation complex and some of which can mediate their
PKA-inducible activities. Evidence which indicates that C/EBPs mediate
the PKA-inducible response on the PEPCK promoter includes: (1) C/EBPs
bind to several of the cis-elements that make up the CRU on the PEPCK
promoter, (2) mutations in these sites which disrupt C/EBP binding also
affect the fold-responsiveness to PKA, (3) over-expression of a dominant
negative C/EBP inhibits PKA responsiveness of the PEPCK promoter in
liver-derived cells, and (4) chimeric GAL4-C/EBPs, which have the DNA-
binding domain of C/EBP replaced by the corresponding domain of the
yeast transcription factor GAL4, can reconstitute the PKA responsiveness
of PEPCK promoter variants which have one or more of the C/EBP sites
substituted with binding si~es for GAL4 (Liu, et al., 1991; Park et al., 1999;
Roesler, et al., 1994; 1996). By using GAL4-derived chimeras of C/EBP, it
was ascertained that both C/EBPa and C/EBP~ can participate in the PKA-
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inducible response and the domains within C/EBPs that participate in the
constitutive and PKA-inducible activities could be analysed without
interference from the endogenous C/EBP proteins within hepatoma cells.
Moreover, since the GAL4 chimeras were constitutively expressed and
localized to the nucleus, it appeared unlikely that the PKA-induced
transcriptional activity of C/EBPs occurred via enhanced translocation to
the nucleus from the cytcsol or due to increased abundance of these
proteins. Rather, the data are consistent with the hypothesis that C/EBPs
contain a PKA-inducible domain, similar to that of CREB.
While it is well-established that C/EBPs can mediate PKA
responsiveness by indirect mechanisms such as enhanced translocation of
C/EBPs from the cytosol to the nucleus in response to elevated cAMP
levels and enhanced expression of C/EBPs in response to cAMP, it is not
generally appreciated that isoforms of C/EBPs possess domains which
contain an intrinsic PKA-inducible activity independent of direct
phosphorylation by PKA (Metz and Ziff, 1991; Pelletier, et aI., 1998). This
intrinsic activity may only manifest itself within certain promoter contexts
due to the involvement of other so-called "accessory" factors. Unlike
CREB, C/EBPa is not a substrate for PKA and, to date, there have been no
observations published that indicate C/EBPa interacts with any co-
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activator molecules. There is evidence that CREB binding protein
activates C/EBPa-dependent transcription and that these two proteins co-
localize to the pericentromeric chromatin but there is no direct evidence
that C/EBPa and CREB binding protein physically interact (Erickson, et al.,
2001; Schaufele, et al., 2001). The N-terminus of C/EBP~ directly interacts
with a homologue of CREB binding protein in vivo and cotransfection
experiments indicate that this CREB binding protein homologue
potentiates the activation of a C/EBP responsive gene by C/EBP~ (Mink, et
al., 1997). Exactly how C/EBP proteins induce or repress expression, how
they interact with co-activators and how and if they are post-
translationally modified to mediate their hormonal response has yet to be
elucidated.
2.5 Objectives
The ultimate objective of this thesis is to identify the regions within
the transactivation domains of C/EBPa and C/EBPP that are required to
mediate the PKA-inducible response and, to a lesser extent, the
constitutive activity on the PEPCK promoter. A significant amount of
information has been gathered about the regions of C/EBPa responsible
for mediating its constitutive transcriptional activation of multiple gene
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promoters. However, as the work in this thesis will outline, the regions of
a transcription factor that are important for mediating the constitutive and
hormone inducible response may be distinct. Many levels of regulation
are required to control the complex milieu of metabolic processes in each
tissue under multiple hormonal and dietary stimuli. This thesis will
outline how different domains of C/EBPa mediate a PKA-inducible
response depending on which cis-element it occupies on the PEPCK
promoter. Not only do different transcription factors mediate hormonal
responsiveness and constitutive activity via distinct domains, the domains
of the transcription factor that mediate the inducible activity may vary
depending on which cis-element it occupies on the promoter. This
observation suggests another level of transcriptional regulation in the
already extremely complex field of gene expression regulation.
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The specific objectives of this thesis are:
(1) To define and characterize the amino acids within the C/EBPa and
C/EBP~ transactivation domains that are required to mediate the PKA
response on the PEPCK promoter within hepatoma cells.
(2) And, once the objective 1 is completed, to elucidate if the
importance of the indicated amino acids are determined and/or influenced
by the cis-element it occupies within the cAMP response unit on the
PEPCK promoter.
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3. MATERIALS AND METHODS
3.1 Reagents
All reagents used for this thesis were of molecular biology or
analytical grade as appropriate. In Table 3.1, the names of the reagents
and the suppliers are listed. Table 3.2 indicates the addresses of the
individual suppliers from which the reagents in Table 3.1 were obtained.
Table 3.1: List of Reagents and Suppliers
Reagent Supplier
Absolute Ethanol BDH
Acetate BDH
Acetyl-CoA Pharmacia
Acrylamide Bio-Rad
Agarose Bio-Rad
Ammonium Persulphate Bio-Rad
Ammonium Acetate BDH
Aprotinin Sigma
Adenosine Tri-Phosphate (ATP) Boehringer
Mannheim
Bio-RAD Protein Assay Dye Reagent Bio-Rad
Concentrate
Bovine Serum Albumin ICN
Bromophenol Blue Sigma
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Reagent Supplier
Calcium Chloride BDH
Chloramphencicol BDH
Chloroform BDH
Coomassie Brilliant Blue Stain Sigma
Diethylpyrocarbonate (DEPC) BDH
Dinucleotide Triphosphate (dNTP) Pharmacia
Dimethylsulfoxide (DMSO) Sigma
2,5-Diphenyloxazole (PPO) Sigma
Dithiothreitol (DTT) Promega
Ethidium Bromide Sigma
Ethylenebis (oxyethylenenitrilo) BDH
Tetraacetic Acid
Ethylene-Diamine Tetraacetic Acid Disodium BDH
Salt (EDTA)
Glacial Acetic Acid BDH
D-Glucose BDH
Glutathione-Sepharose Beads Pharmacia
Glycerol BDH
Glycine BDH
Glycogen Azure Sigma
Hydrochloric Acid (HCI) BDH
N-2-Hydroethylpiperazine-N'-2 USB
-Ethane Sulphonic Acid (HEPES)
Isobutanol BDH
Isopropyl-~-D-thiogalactopyranoside(IPTG) USB
Isopropanol BDH
Low Melting Point (LMP) Agarose Bio-Rad
Magnesium Chloride (MgCh) BDH
~-~ercaptoethanol Sigma
Methanol BDH
N,N'-Methylene-Bis-Acrylamide Bio-Rad
Nonident NP-40 BDH
0-Nitrophenyl-~-D-Galactopyranoside(ONPG) Boehringer
Mannheim
Pepstatin A Sigma
Phenol Sigma
Phenylmethanesulfonyl Fluoride (PMSF) Sigma
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Reagent Supplier
Phosphate Buffered Saline RDH
l,4-Piperazine Diethane Sulfonic Acid, Sigma
Sodium Salt (PIPES)
Polyethylene Glycol (PEG) Sigma
Potassium Chloride BDH
Sodium Chloride (NaCI) BDH
Sodium Bicarbonate (Na2C03) BDH
Sodium Deoxycholate BDH
Sodium Dodecyl Sulphate (SDS) Pharmacia
Sodium Hydroxide (NaOH) BDH
Sodium Orthovanadate Sigma
N,N,N',N'-Tetramethylenediamine (TEMED) Sigma
Toluene BDH
Tris-HCI GIBO-BRL
Trypsin-EDTA GIBCO-BRL
Tween-20 Sigma
Urea BDH
Xylene Cylanol FF Sigma
Zinc Chloride BDH
Reagents for Bacterial Growth
Ampicillin ICN
Bacto-Agar DIFCO
Bacto-Tryptone DIFCO
Bacto-Yeast Extract DIFCO
Kanamycin Boehringer
Mannheim
M13K07 Helper Phage NEB
Cell Stock Freezing Media (DMSO) GIBCO-BRL
Dulbecco's Modified Eagle Medium: Nutrient GIBCO-BRL
Mixture F-12 (Ham)(l:l) -with Glutamine
Fetal Bovine Serum (Mexican) GIBCO-BRL
Enzymes
T4 DNA ligase GIBCO-BRL
DNA Polymerase I, Klenow Fragment- Promega
Labeling Grade
RNAse A Boehringer
Mannheim
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Reagent Supplier
RNAseTl Boehringer
Mannheim
RNasin GlBCO-BRL
Taq DNA Polymerase- from Thermophilis GlBCO-BRL
Aquaticus
T7 RNA Polymerase Promega
Restriction Endonucleases NEB
Radioactive Substrates
3H-Acetyl-CoA Perkin-Elmer
I 35S_Methionine Perkin-Elmer I
Table 3.2: Names and Addresses of Reagent Suppliers
Supplier Addresses
BDH British Drug House, Saskatoon,
Saskatchewan, Canada
Bio-Rad Bio-Rad Laboratories, Mississauga,
Ontario, Canada
Boehringer Boehringer Mannheim Canada Ltd.,
Mannheim Laval, Quebec, Canada
DlFCO DlFCO Laboratories, Detroit, Michigan,
USA
GlBCO-BRL Bethesda Research Laboratories,
Burlington, Ontario, Canada
lCN ICN Biomedical Canada Ltd.: St.
Laurent, Quebec, Canada
NEN-Mandel Mandel Scientific Company, Guelph,
Ontario, Canada
Perkin-Elmer Perkin Elmer Life Sciences, Canada,
Woodbridge ,Ontario, Canada
Pharmacia Pharmacia LKB Biotechnology Ltd., Baie
d'Urfe, Quebec, Canada
Promega Fischer Scientific, Nepean, Ontario,
Canada
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Suppliers Addresses
Santa Cruz Santa Cruz Biotechnology, Inc., Santa
Biotechnology Cruz, California, USA
Sigma Sigma Chemical Co., St. Louis, Missouri,
USA
United States United States Biochemical Corporation,
Biochemical Cleveland, Ohio, USA
(USB)
3.2 Bacterial Strains and Media Preparation
During the course of this thesis, Escherichia coli (E. coli) strain,
NM522, was utilized for all cloning manipulations and propagation unless
otherwise indicated. This strain was described in detail by Gough and
Murray (1983) and Woodcock, et al., (1989).
Luria-Bertani Ampicillin (LBA) plates were used to propagate the
bacterial cells when they were transformed with an expression plasmid
with ampicillin resistance. These plates were prepared by combining 10 g
of bacto-tryptone, 5 g of bacto-yeast extract, 10 g of NaCl, and 15 g of agar
in 1 L of double distilled water (ddH20.) This solution was sterilized via
autoclavation for at least 20 minutes at 15 Ib/sq. in. After the solution was
sufficiently cooled, amphicillin was added to the medium to a final
concentration of 50 Ilg/mL and the plates were poured.
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LB liquid medium was used to prepare NM522 competent cells
after overnight incubation at 37°C with nutation. This medium was
prepared to the same final concentration of reagents as above up to a 200
mL volume except no antibiotic was added after sterilization and no agar
was added to the medium.
Terrific Broth (TB) as described by Sambrook, et al., (1989), was
used to propagate bacterial cells in a liquid medium grown overnight at
37°C with nutation. This medium was prepared by combining 4.8 g of
bacto-tryptone, 9.6 g of bacto-yeast extract and 1.6 mL of glycerol in 400
mL of ddH20. This mixture was autoclaved as above. After the mixture
cooled to a sufficient degree, a sterile solution of 0.17 M KH2P04 and 0.72
M I<2HP04 (K-Salts) and the appropriate antibiotic were added to the
medium using sterile technique.
K-Salts were prepared by combining 2.3 g of KlliP04 and 12.54 g of
I<2HP04 per 100 mL of ddH20 and this mixture was autoclaved at 15Ib/sq.
in. for 20 minutes.
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3.3 General Molecular Cloning Procedures
All protocols in this section were at least partially based upon those
presented in Sambrook, et al., (1989). Unless otherwise specified, all
centrifugation was performed at 12 500 rpm at room temperature.
3.3.1 Preparation of Competent Cells
An overnight culture was prepared from a singlz colony of E. coli
inoculated into 5 mL of LB broth in a 50 mL sterile conical. The culture.
was grown overnight at 37°C with nutation to obtain a saturated bacterial
solution. A 1:200 dilution of the saturated culture was used to inoculate
200 mL Luria Broth and a sample was removed to indicate the optical
density (O.D.) of the cultur~ at zero time. The culture was grown at 37°C
with nutation until the culture reached an O.D.s90 of 0.375. The culture
was decanted into 4 equal volumes into 50 mL pre-chilled sterile conical
tubes and incubated on ice for 10 minutes before being pelleted at 3000
rpm for 7 minutes at 4°C on a Clinical Centrifuge from the International
Equipment Co. The supernatant was decanted and the cell pellets were
resuspended in 10 mL of ice-cold CaCh solution consisting of 15%
glycerol, 60 mM CaCh and 10 mM PIPES, pH 7.0. The washing step was
repeated and the cell pellets were then suspended in 10 mL of CaCh
55
solution and incubated on ice for 10-30 minutes. The cell pellets were
resuspended in 2 mL of CaCh solution and dispensed into pre-chilled
sterile tubes and stored at -BO°C.
3.3.2 Transformation of Competent Bacterial Cells
An aliquot of 100 JlL of competent cells was introduced to
approximately 1 Jlg of plasmid DNA in a 12 mL falcon tube and incubated
for 10-30 minutes on ice. The tubes were heat-shocked at 42°C for 2
minutes to allow for bacterial cell transformation. The heat-shocked cells
were incubated on ice for 2 minutes before being plated on an LB agar
plate with the appropriate antibiotic and incubated overnight at 37°C.
Single colonies of bacteria were selected and propagated for small scale
plasmid isolation and further diagnostics or genetic manipulation.
3.3.3 Small Scale Plasmid DNA Isolation
A 5 mL culture of Terrific Broth with the appropriate antibiotic was
inoculated with a single E. coli colony and incubated overnight at 37°C
with nutation. The protocol used to isolate small scale plasmid DNA was
based upon the protocol of Lee and Rasheed, (1990). The plasmid DNA
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pellet was resuspended in 25 JlL IX TE (10 mM Tris-HCl, pH 7.5, 1 mM
EDTA, pH 8.0) containing 0.1 JlL of 10 mg/mL RNase.
3.3.4 Large Scale Plasmid DNA Isolation
A 400 mL culture of Terrific Broth with the appropriate antibiotic
was inoculated with a 5 mL culture of a single E. coli colony (described
above) and the 400 mL culture was incubated overnight at 37°C with
nutation. The procedure used was based upon the alkaline lysis method
described by Sambrook, et al., (1989). The plasmid DNA pellet was
resuspended in O.lX TE to a concentration of 1 Jlg/JlL as determined by
acquiring the optical density at OD260 in which 1.0 corresponds to 50 Jlg
plasmid DNA. A ratio of OD260/0D280 which registered between 1.7 to 1.8,
indicated a relatively pure plasmid preparation.
3.3.5 Agarose Gel Electrophoresis
Unless otherwise specified, agarose gel electrophoresis was
typically preformed on a 101<> agarose gel in 1 X TAE buffer and 0.5 Jlg/mL
ethidium bromide. The running buffer was 1 X TAE cOf\sisting of 40 mM
Tris-Acetate and 1 mM EDTA at pH 8.0. Samples were mixed with an
appropriate volume of 5X agarose gel sample buffer consisting of 500/0
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glycerol, 50 mM EDTA, pH 8.0 and traces of bromophenol blue and
xylene cylanol FF before being loaded onto the gel. Electrophoresis
typically was carried out at between 90 and 110 volts until the appropriate
band resolution was achieved.
3.3.6 Restriction Digests
Typically, digestion of DNA with restriction enzymes were carried
out in 20 ilL of ddlliO and the reaction consisted of approximately 1 Ilg
DNA, 2 ilL of lOX buffers (appropriately selected according to the
manufacturer's recommendations), and 1-2 U of each restriction
endonuclease. The samples were incubated at 37°C (unless otherwise
indicated by the manufacturer) for at least 1 hour and not more than 12
hours.
3.3.7 DNA Fragment Isolation and Ligation Reaction
After the appropriate band separation was achieved by agarose gel
electrophoresis, a small section dir~ctly under the band of interest was
excised and the void was filled with 0.9% low melting-point agarose
(LMP) and 0.5 flg/mL ethidium bromide. After the LMP agarose
congealed, the electrophoresis was reinitiated for the appropriate amount
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Table 3.3: Plasmids Utilized For Gene Cloning
Plasmid Cloning Cloning Origin of Insert
Name Vector Site
C/EBPa pBK-CMV EcoRI- 18R-C/EBPa
HindIII
C/EBPPP pBK-CMV EcoRI- pM1-C/EBPPP
Xba1
C/EBPaa CMV- Pst1-Xbal 18R-C/EBPaa
C/EBPaa
C/EBPap CM\/- Kpn1- CMV-C/EBPPP
C/EBPaa Xba1
C/EBppa pBK-CMV EcoRI- CMV-C/EBPaa,
Kpn1, CMV-C/EBPPP
Kpn1-
Xba1
C/EBPP pBK-CMV HindIII- pBluescript II
Xba1 KS-NFIL6
GAL4-a60- pM2 BamHI- 19R-C/EBPa 6-
217 Pst1 60-217
GAL4-a72- PM2 BamHI- 19R-C/EBPa 6-
217 Pst1 72-217
GAL4-aL\CR1 GAL4-a50- BamHI- pM2-C/EBPa 60-
217 Pst1 217
GAL4- GAL4·a.50- BamHI- pM2-C/EBPa 72-
aL\CR1,2 217 Pst1 217
GAL4-aL\CR3 GAL4-a50- BamHI- GAL4-a 112-217
217 Pst1
GAL4-aL\CR2 GAL4-a50- BamHI- 19R-C/EBPa 6-
217 Pst1 72-217
GAL4-pCR1 GAL4-p1- NaeI-SacII Oligonucleotide
108
GAL4-pCR2 GAL4-p1- NaeI-SacII Oligonucleotide
108
PM1-HA pM1 BglII- pHA3
EcoRI
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Plasmid Cloning Cloning Origin of Insert
Name Vector Site
PM2-HA pM2 BglII- pHA3
EcoRI
PM3-HA pM3 BglII- pHA3
EcoRI
HA-C/EBPa pMl-HA EcoRI- CMV-C/EBPa
HindIII
HA-C/EBP~a pMl-HA EcoRI- CMV-C/EBP~a
Xbal
HA-C/EBPaa pMl-HA EcoRI- CMV-C/EBPaa
Xbal
HA-C/EBPa~ pMl-HA EcoRI- CMV-C/EBPa~
Xbal
HA-C/EBP~~ pMl-HA EcoRI- CMV-C/EBP~~
Xbal
HA-a50-2l7 pM3-HA EcoRI-Pstl GAL4-a50-2l7
Pst-Xbal GAL4-CIEBPa
HA-a~CRl pMl-HA EcoRI- GAL4-a~CRl
Sacl
HA-a~CRl,2 pMl-HA EcoRI- GAL4-a~CRl,2
Sacl
HA-a~CR2 pMl-HA EcoRI- GAL4-a~CR2
Sacl
HA-a~CR3 pMl-HA EcoRI- GAL4-a~CR3
Sacl
HA-C/EBP~ pMl-HA HindIII- GAL4-CIEBP~
Xbal
HA-~CRl HA-C/EBP~ EcoRI- GAL4-~CRI
Xbal
HA-~CR2 HA-CIEBP~ EcoRI- GAL4-~CR2
Xbal
FGC-aTA FG-CREB EcoRI-Pstl pMl-C/EBPa
FGC-a50-2l7 FG-CREB BamHI- GAL4-aSO-2l7
Pstl
FCG-a~CRl FG-CREB EcoRI-Pstl GAL4-a~CRl
FCG-a~CR2 FG-CREB EcoRI-Pstl GAL4-a~CR2
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Plasmid Cloning Cloning Origin of Insert
Name Vector Site
FCG-a~CR3 FG-CREB EcoRI-Pst1 GAL4-a~CR3
FCG-aTM FG-CREB EcoRI-Pst1 GAL4-aTM
355 -C/EBPa pTZ-18R BamHI- RSV-C/EBPa
HindIII
355 -a50-217 pTZ-18R BamHI- FeG-aTA
Pst1
355 -a~CR1 pTZ-18R BamHI- FCG-a~CR1
Pst1
355 -a~CR2 pTZ-18R BamHI- FCG-a~CR2
Pst1
355 -a~CR3 pTZ-18R BamHI- FCG-a~CR3
Pst1
355 -aTM pTZ-18R BamHI- FCG-aTM
HindIII
The plasmids designed above, with the exception of pM1-HA,
. pM2-HA, pM3-HA, the FG-CREB constructs and the 355_ constructs were
designed as expression vectors for Western analysis, and transient
transfection analysis. The pM1-HA, pM2-HA, pM3-HA and FG-CREB
vectors were designed to act as parent vectors for the construction of the
indicated plasmids in Table 3.3 and the 355 chimeras were used for in vitro
protein expression. All plasmids were subjected to diagnostic restriction
digests and/or automated DNA sequencing to verify the identity of each
construct. The pM1, pM2 and pM3 vectors were described in Sadowski
and Ptashne, (1989).
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The parent plasmid used to construct CMV-C/EBPa was 18R-
C/EBPa that was mutated via Stratagene's QuikChange Mutagenesis
technique to introduce a Kpnl restriction endonuclease site at the region
of the gene corresponding to amino acid 255 via the primers
5'GGCITGGCTGGTACCCACCCCGAACCTC3' and 5'GAGGTCGGGGT-
GGGTACCAGCCAAGCC3' (ID Labs.) The Kunkel method of site-
directed mutagenesis was used to introduce a Kpnl restriction
endonuclease site into 19R-NFIL6 at the region of the gene corresponding
to amino acid 252 via primer 5'GCCTGCTACGCGGGTACCGGGC-
CGGCGCCCTCGCAG3' (UCDNA.) The region of the genes
corresponding to C/EBPa's and NFIL6's transactivation domain (TA) and
DNA-binding domains (DBD) were now able to be isolated from each
other. The plasmids with these Kpnl sites between the TA and DBD were
now identified as 18R-C/EBPaa and 19R-C/EBP~~,respectively. The 18R-
C/EBPa plasmid insert was ligated in-frame to the pBK-CMV vector
(Stratagene) via EcoRI-HindIII ligation to create C/EBPa. C/EBPa was
subsequently restricted with Pstl-Xbal and ligated with a Pstl-Xbal
digest of 18R-C/EBPaa insert to create C/EBPaa.
To engineer the C/EBPa~ vector and C/EBP~~, the 19R-C/EBP~~
vector was restricted with HindIII-BamHI, introduced into pMl. This
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vector was subsequently rerestricted and the insert was religated into the
pBK-CMV vector via EcoRI-Xbal digestion to create C/EBPpp. To isolate
the P DBD, the C/EBPPP vector was restricted with Kpnl-Xbal and this
insert was ligated in-frame to C/EBPaa to create the plasmid, C/EBPap.
To create the plasmid C/EBppa, a double ligation was performed.
The C/EBPaa vector was restricted with EcoRI-Kpnl to isolate the C/EBPa
TA in soft agar and the C/EBPPP vector was restricted with Kpnl-HindIII
and the C/EBPP DBD was isolated in soft agar. The CMV vector was
restricted with EcoRI-HindIII and isolated in soft-agar as well. The
ligation reaction was typical (Section 3.3.7) except the 7 flL of insert
consisted of 3.5 flL of C/EBP a TA (EcoRI-Kpnl) and 3.5 flL of C/EBP P
DBD (Kpnl-Xbal) to construct the plasmid, C/EBppa.
To create C/EBPP, 19R-NFIL6 was restricted with HindIII-BamHI
and ligated into pBluescript KS II (United States Biochemical). This vector
was subsequently digested with HindIII-Xbal and ligai:ed into the CMV
vector to create CMV-C/EBPp.
In the next series of C/EBPa deletion constructs, the TA domains of
C/EBPa and C/EBPP were compared using the computer program
INTERALIGNvl.O, Stanford and three regions with significant homology
were identified. Plasmids \vere engineered to remove each conserved
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region (CR) within C/EBPa's TA alone and in conjunction with the first 50
amino acids of C/EBPa. pM1-C/EBPa 6-217 was restricted with EcoRI-
Pst1 and introduced into the pTZ-19R vector (United States Biochemical).
This phagemid was used as a template to introduce BamHI sites via the
Kunkel method into the sites corresponding to amino acids 60 and 72
using the primers 5'GACCCGGCCGGATCCAACGAC3' and
5'GAGCACGAGGGATCCATAGAC3', respectively (UCDNA). The
mutant 19R-C/EBPa 6-217 constructs were digested with BamHI-Pst1 and
ligated in-frame to pM2 to create GAL4-a60-217 and GAL4-a72-217.
Because pM1, pM2 and pM3 have the region corresponding to the GAL4
DBD upstream of its multiple cloning site, the proteins expressed using
these plasmids have the GAL4 DBD at its N terminus.
To construct the C/EBPa internal deletion mutants, a GAL4-
C/EBPa construct which contains a BamHI site on the 3' end of the region
corresponding to the first 50 amino acids (Roesler, et aI., 1998).was used as
the ligation vector, (GAL4-a50-217). GAL4-a60-217 and GAL4-a72-217
were digested with BamHI-Pst1 and the inserts were ligated to the
BamHI-Pst1 sites of the GAL4-a50-217 vector to create GAL4-a~CR1 and
GAL4-a~CR1,2. A pM1-C/EBP construct consisting of the amino acids
112-217 from C/EBPa (Roesler, et al., 1998) was digested with BamHI-Pst1
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and the insert was ligated to GAL4-a50-217 to create the GAL4-a~CR3
expression construct. Finally, the 19R-C/EBPa mutant with the BamHI
restriction endonuclease site at the region corresponding to amino acid 60
was restricted with EcoRI-BamHI and the insert was ligated to the pM1
vector. This construct was subsequently restricted with BamHI-Pstl and
ligated with the insert corresponding to the amino acids 72-217 to create
the plasmid GAL4-a~CR2.
The C/EBPP mutant GAL4-C/EBPP was described in Park, et al.
1999. GAL4-I3CR1 and GAL4-pCR2 were created by restricting the parent
construct with NaeI-SacII and replacing the insert with oligonucleotide
primers with extensive mutations at the regions corresponding to CRI or
CR2. The ID Lab primers which created GAL4-~CRI were
5'GGCGGCGGGCGCGAGCGGCTCCAGGTAGGGGCTGAAGTCGATG
GCGCGCGCGGCCGCGCCGGCGGCC3' and 5'GGCCGCCGGCGCG-
GCCGCGCGCGCCATCGACTTCAGCCCCTACCTGGAGCCGCTCGCG
CCCGCCGCCGC3' . The primers used to create GAL4-~CR2 were 5'
GGCGGCGGGCGCGAGCGGCGCCGCGGCGGGGGCGGCGGCGACGG
CGCGCTCGTGCTCGCCGATGGCC3' and 5'GGCCATCGGCGAGC-
ACGACGCCGCCGTCGCCGCCGCCCCCGCCGCGGCGCCGCTCGCGC
CCGCCGCCGC3'.
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In the next series of mutant constructs, the majority of the above
constructs were ligated in-frame to a plasmid constructed to contain a
region which corresponds to the two adjacent hemagglutinin (HA) tags.
The pM1, pM2 and pM3 plasmids were used as templates and their GAL4
coding regions were excised via a BglII-EcoRI digest and the vector was
isolated in soft-agar. Using the pHA3 vector (designed by Charest, et al.
1995), two PCR primers were created to hybridize with the region
upstream of the Kozak sequence of HA3 and introduce a BglII site at the 5'
end of the forward primer (5'GACCGGAAGATCTCA-
CCATGATCTITTAC3') and the second primer was designed to introduce
an EcoRI site between the second and third HA site of pHA3
(5'ATATGGATAGAATTCTGCATAGTCCGGGACGTC3' (ID Labs.) After
PCR amplification of this region, the PCR product was electrophoresed on
a 1% agarose gel and isolated from soft-agar with an Agarose Gel DNA
Extraction Kit (Boehringer Mannheim) as per the manufacturer's
instructions. The purified HA2 PCR product was restricted with BglII-
EcoRI and the digest was ligated in-frame to each pM vector fragment
creating the vectors, pM1-HA, pM2-HA and pM3-HA.
To create HA-C/EBPa and HA-C/EBP~a, the CMV-C/EBPa vector
and CMV-C/EBP~avectors were digested with EcoRI-HindIll and ligated
67
into the pM1-HA vector. HA-C/EBPaa, HA-C/EBPap, HA-C/EBPPP and
HA-C/EBPP were created by restricting the corresponding CMV parent
vectors described above with EcoRI-Xba1 and ligating the inserts into
pM1-HA.
The C/EBPa deletion constructs GAL4-a~CR1, GAL4-a~CR1,2,
GAL4-a~CR2, GAL4- ~CR3 were digested with EcoRI-Sac1 and isolated
in soft agar. Each insert was ligated to the HA-C/EBPa vector. HA-a50-
217 was created by ligating the EcoRI-Pst1 TA fragment of GAL4-a50-217
to the pM3-HA2 vector. This vector was subsequently restricted with
Pst1-Xba1 and ligated with the Pst1-Xba1 C/EBPa DBD insert. To create
HA-C/-EBP~, HA-~CR1 and HA-~CR2, the corresponding GAL4-C/EBP~
mutants were restricted with EcoRI-Xba1 and ligated int0 pM1-HA.
In order to create the in vitro expressed proteins, a series of FGC
constructs had to be made. GAL4-a~CR1, -a~CR2, -a~CR3, C/EBPa. and
C/EBPa TM were restricted with EcoR1-Pst1 and each insert was ligated
into the FG-CREB vector (Roesler laboratory, unpublished data). FGC-
0.50-217 was created by restricting GAL4-a.50-217 and introducing this
insert into FG-CREB. To create 355 -C/EBPa, 355 -a~CR1, 355 -a~CR2, 355 -
a~CR3, and 355 -0.50-217, the respective FGC-C/EBPa constructs were
restricted with BamHI-PstI and these DNA fragments are introduced into
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the pTZ-18R vector. To create 355 -C/EBPaTM, the FGC-aTM vector was
restricted with BamHI-HindIII and this DNA fragment was introduced
into pTZ-18R.
3.5 Culture of Human Hepatoma HepG2 Cells
Human hepatoma HepG2 (ATCC HB8065) cells were propagated at
37°C and 5% C02 in Dulbecco's Modified Eagle Medium Nutrient Mixture
F-12 (Ham) (1:1)- with L-glutamine and containing 100/0 Fetal Bovine
Serum. The cell line was propagated twice a week via trypsinization at a
1:4 or 1:5 dilution on 100 mm tissue culture plates.
HepG2 stocks of 100 mm tissue culture plates were prepared by
trypsinizing the plates and resuspending the detached hepatoma cells in
10 mL of D-MEM cell media. The cells were centrifuged at 3000 rpm at
4°C for 5 minutes, the supernatant was removed and replaced with 1 mL
of cell stock freezing media containing fetal bovine and calf serum, and
10°,10 DMSO. The cells were subsequently frozen down in Liquid
Nitrogen.
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3.6 Transient Transfection of Human HepG2 Cells
Transient transfection of HepG2 cells was carried out as indicated
by Sambrook et al., (1989). Four hours before transfection, the adherent
cells on a 100 mm plate were trypsinized and split into eight 60 mm plates
or four 100 mm plates to render them approximately 700k confluent. The
cells were transfected with the appropriate expression vectors, RSV-~gal,
pTZ-19R and pMT-C where appropriate, to a total amount of 12.5
Jlg/plate. The transfection mixture was composed of 95 JlL of 2 M CaCh
and 375 ~L of 2X HBS (1.1915 g HEPES, 1.636 g NaCI, 0.2162 g Glucose,
0.5 mL of 2 M KCI, and 1.5 mL of 0.1 M NailiP04.2 H2O in 100 mL H2O)
and 625 ~L of ddH20. The solutions and DNA were allowed to incubate
for 20 minutes to form a fine CaCh-DNA precipitate before 500 JlL was
dispensed to each plate. After the cells were incubated at 37°C with 5°k
C02 overnight, the medium was aspirated and the plates were rinsed with
PBS. D-MEM media plus 80 JlM ZnCI was added to the plates and they
were allowed to incubate at 37°C and 50/0 CO2 for 24 hours.
3.6.1 Transient Transfection Analysis
The medium was aspirated and the adherent cells were rinsed with
IX PBS before 0.5 mL of Harvesting solution (40 mM Tris-HCI, pH 7.5, 1
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mM EDTA, 150 mM NaCI) was added and the cells were scraped with a
rubber policeman and kept on ice. The cells were transferred to a 1.5 mL
eppendorf tub~ and quickly centrifuged to pellet the cells. The Harvesting
solution was aspirated and the cells were resuspended in 150 p.L 0.25 M
Tris-HCI, pH 7.8. The cells were vortexed briefly and subjected to three
freeze-thaw cycles at -80°C/37°C, respectively. The cells were centrifuged
at 12 500 rpm at 4°C for 10 minutes and a 15 ilL aliquot and a 3.5 ilL
aliquot was removed for p-galactosidase assay and protein analysis. The
remainder of the cell suspension was heat-treated at 65°C for 5 minutes to
inactivate competing enzymes for the Chloramphenicol Acetyltransferase
(CAT) assay and aliquots of 30 ilL and 6.5 ilL were removed for the CAT
assay and CAT protein analysis.
3.6.2 p-galactosidase Assay
A solution consisting of 66 ilL o-Nitrophenol-p-D-
galactopyranoside (ONPG) (4 mg/mL ONPG in 0.1 M Sodium Phosphate
buffer, pH 7.5), 3 ilL ot 100X MgCh (0.1 M MgCh and 5 M p-
mercaptoethanol) and 201 J,lL of 0.1 M Sodium Phosphate buffer, pH 7.5
(41/9 ratio of 0.1 M NailiP04 and 0.1 M NalliP04, respectively) was added
to each 15 ilL sample. The samples were incubated in a 37°C water bath
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until a yellow, soluble product was formed. This process was timed from
the point of water bath incubation of the samples until 500 J.lL of 1 M
NazC03 was added to the yellow product. The absorbance of each sample
was measured at 420 run and the data was recorded.
3.6.3 CAT Assay
The CAT mix was composed of 10 ilL of 5 mM chloramphenicol
(dissolved in 0.25 mM Tris-HCI, pH 7.5), 1.5 J.lL of 3H-Acetyl-CoA, 0.075
J.lL of 20 mM Acetyl-CoA, and 8.425 IJL of 75 mM HCl. This 20 ilL volume
was added to 30 J.lL heat-treated samples and the samples were incubated
for up to 3 hours in a 37°C water bath. The reaction was stopped upon the
addition of 0.5 mL of 7 M Urea.
The samples were introduced to 10 mL of Toluene containing 0.8°1<>
2,5-Diphenyloxazole (PPO~ and the samples were incubated for 15
, minutes at room temperature and subsequently counted on a Beckmann
LS 6500 Scintillation Counter for 1.0 minute.
3.6.4 Protein Quantitation of Transfected Cells
A 1 mL volume of Bio-RAD Protein Assay Dye Reagent
Concentrate diluted 1/4 with ddH20 was added to each protein sample
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and the samples were incubated at room temperature for 5 minutes before
being read on a spectrophotometer at O.D.595. A concentration standard
curve of Bovine Serum Albumin (BSA) ranging from 0-10 Jlg/mL Bio-RAD
Reagent was subjected to spectrophotometric analysis to identify the slope
of the standard curve.
3.7 Determination of Protein Expression via Western Analysis
3.7.1 Preparation of HepG2 Cell Nuclear Extracts
The transfected tissue culture HepG2 cells (Section 3.5) were rinsed
with IX PBS, harvested with a rubber policeman and pelleted. The cell
pellet was resuspended in 400 JlL cold buffer A (10 mM HEPES, pH 7.9, 10
mM KCI, 0.1 mM EDTA, 0.1 mM EGTA, 1 mM DTI, 0.5 mM PMSF) and
the cells were allowed to swell on ice for 15 minutes. Subsequently, 25 JlL
of look Nonid~t NP-40 was added, the tube was vortexed and centrifuged
for 30 seconds at 12 500 rpm. The nuclear pellet was resuspended in 50 JlL
of ice cold buffer C (20 mM HEPES, pH 7.9, 0.4 M NaCI, 1 mM EDTA, 1
mM EGTA, ImM DTT and 1 mM PMSF). The tube was vigorously rocked
at 4°C for 30 minutes, the nuclear extract was pelleted and the supernatant
was introduced to a fresh tube. Aliquots of the supernatant fraction were
subjected to SDS-PAGE analysis.
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3.7.2 Transient Transfection Analysis Using Lipofectamine Reagent
Four hours before transfection, the adherent cells on a 100 mm
plate were trypsinized and split into four 100 mm plates to render them
approximately 70% confluent. A solution of 300 ilL of D-MEM medium
was incubated with 5 Ilg of lipofectamine reagent (Invitrogen) and 6 Ilg of
the expression plasmid. The solutions and DNA were allowed to incubate
for 20 minutes before being dispensed to each plate. After the cells were
incubated at 37°C with 5°1<> C02 overnight, the medium was aspirated and
the plates were rinsed with PBS. D-MEM medium was added to the
plates and they were allowed to incubate at 37°C and 5% C02 for 24 hours.
3.7.3 Recovery of Protein Lysates After Lipofectamine Transient
Transfection
After transfection of tissue culture cells with the appropriate
expression plasmid and RSV- Pgalactosidase, the confluent, adherent cells
were rinsed with cold IX PBS (140 mM NaCI, 27 mM KCI, 100 mM
Na2HP04-7 H20 and 18 mM KlliP04) before being scraped from the plates
with 200 JlL RIPA buffer (1 X PBS, 1% Nonidet-NP-40, 0.50/0 (wjv) sodium
deoxycholate, 0.1 01<> SDS, 100 Ilg/mL PMSF, 2 Ilg/mL aprotinin, 1 mM
sodium orthovanadate and 1 IlglmL pepstatin A.} Lysates were
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centrifuged at 12 000 rpm for 15 minutes at 4°C, the supernatant was
transferred to a fresh tube. An appropriate volume of 5X SDS sample
buffer (50 mM Tris-HCl, pH 6.8, 2°,10 SDS, 400 mM 2-mercaptoethanol, 100/0
glycerol and traces of bromophenol blue) was added to the sample The
concentration of protein was quantified by ~-galactosidaseassay.
3.7.4 Electrophoresis of Protein Lysates for SDS-PAGE and Western
Blotting
Protein lysates were resolved on a 12% SDS-PAGE gel composed of
12% acrylamide: N,N'-methylene-bis-acrylamide (29.2:0.8), 375 mM Tris-
HCI, pH 8.8, and 0.1°,10 SDS in the resolving gel and 5 % acrylamide: N, N'-
methylene-bis-acrylamide (29.2:0.8), 130 mM Tris-HCl, pH 6.8, and 0.1 %
SDS in the stacking gel. The gel was polymerized following the addition
of 0.1% APS and 0.04% TEMED. The running buffer was composed of 25
mM Tris-HCI, 250 mM glycine and 0.1% SDS. After the protein lysates
had been properly quantified, approximately 20 Ilg was loaded onto the
SDS-PAGE gel on a Bio-Rad Mini Protean® II Apparatus at and run at 100
volts until the bromophenol blue dye had runoff the gel.
The separate bands were then transferred onto a nitrocellulose or
PVDF membrane using a Bio-Rad Trans-blot apparatus at 120 volts for 1
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hour at 4°C. The transfer buffer was composed of 39 mM glycine, 48 mM
Tris-HCl, and 20% methanol. The membranes were then rinsed with
blocking buffer (lX PBS and 0.04% Tween-20 (PBST» and 5% Bio-Rad
Blotting Grade Blocker Non-Fat Dry Milk for 1 hour at room temperature.
The blocked membrane was then incubated with 1:1000 of the appropriate
1° antibody (Santa Cruz, Biotechnology) in blocking buffer overnight at
4°C with gentle nutation. After overnight hybridization, the membrane
was washed extensively with blocking buffer and subsequently incubated
with a 1:10 000 dilution of the appropriate 2° antibody conjugated to
horseradish peroxidase (Santa Cruz, Biotechnology) for 1 hour at room
temperature. The membrane was again extensively washed in blocking
buffer and finally it was washed twice with PBST. The antibody-protein
complexes were detected using the NEN-Mandel Renaissance®
chemiluminescent detection kit and Kodak X-OMAT film at room
temperature.
3.8 Site-Directed Mutagenesis
3.8.1 Stratagene's QuikChange™ Site-Directed Mutagenesis
Oligonucleotide primers were designed to perfectly hybridize with
the same sites on the sense and antisense template except for a mutation
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introduced at the center of the primers. A PCR reaction was designed as
per the manufacturer's instructions. Upon completion of the
thermocycling, 1 J.lL of the restriction enzyme Dpn 1 was introduced to
each sample for 1 hour at 37°C to cleave the methylated parent strands
specifically. At least 1 J.lL of the Dpnl treated DNA samples were
transformed in NM522 cells and plated onto LB plates with the
appropriate antibiotic. Colonies were selected and tested for the
mutations via restriction analysis or DNA sequencing.
3.8.2 Kunkel Method of Site-Directed Mutagenesis
3.8.2.1 Prepar:ltion of Single-Stranded DNA
In order to perform the Kunkel method of site-directed
mutagenesis, the parent phagemid was transformed into CJ236dut-ung- E. coli
to create uracil-containing DNA. A colony was selected and grown in 5
mL of 2XYT media (16 g bacto-tryptone, 10 g bacto-yeast, and 5 g NaCl
autoclaved as above) and 50 J.lg/mL ampicillin at 37°C in a shaking
incubator. A 50 mL 2XYT + ampicillin culture was inoculated with 500 J.1L
of the saturated culture and 200 J,1L of M13K07 phage and the culture was
incubated at 37°C with shaking for 1 hour. After this time, a final
concentration of 75 J,1g/mL Kanamycin was added to the overnight culture.
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To isolate the single stranded, uracil containing nucleic acid
(ssDNA), the culture was pelleted at 7 000 g on a Clinical Centrifuge from
the International Equipment Co. for 15 minutes at 4°C. The supernatant
was transferred to a fresh tube and 1/4th volume of 3.5 M NH4-Acetate
and 200/0 PEG solution was introduced and the solution was incubated on
ice for 30 minutes. The centrifugation step was repeated, the pellet was
resuspended in 200 J..lL of 1 XTE and the sample was extracted twice with
phenol and once with chloroform to remove impurities. The single
stranded DNA was precipitated with 1/10th volume of 3 M NaOAc (pH
5.2) and 2 volumes of absolute ethanol. The single stranded DNA was
rinsed with 700/0 ethanol and allowed to air-dry before being resuspended
in IX TE to a concentration of 1 J,Lg/mL.
3.8.2.2 Performing Kunkel Method Site-Directed Mutagenesis
To perform the mutagenesis reaction, 1 J,Lg of ssDNA, 10 pmol of
phosphorylated oligonucleotide containing the mutation, 1 flL of lOX PEl
buffer (200 mM Tris, pH 7.5, 100 mM MgCh, 500mM NaCI, 10 mM DlT)
up to 10 flL ddfuO were combined and heated for 5 minutes at 20°C above
the Tm of the primer. The sample was allowed to cool slowly to allow
proper primer-template hybridization. Next, 10 flL of PE3 buffer (1 flL of
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PE2 buffer (200 mM Tris, pH 8.0, 100 mM MgCh, 10 mM DTI), 1 JlL of 10
mM dNTP's, 1 f.lL of 10 mM ATP, 1 ).1L of 5 mM ligase, 2 U of Sequenase
up to 10 ).1L H20) was added to the sample and it was incubated for 2
hours at room temperature before being transformed into NM522 cells
and plated on LBA plates overnight at 37°C. Colonies were selected and
tested for the mutation by restriction analysis or sequencing.
3.9 Polymerase Chain Reaction
The Polymerase Chain Reaction (PCR) mixture consisted of 10
pmol of both the forward and reverse primers, 2 ilL of 50 mM MgCh, 2 ilL
. of 10 mg/mL dNTP's, 5 :lL of IX PCR buffer, 1 Unit of Taq DNA
polymerase, and approximately 100 mmol template in 50 ilL ddH20. The
thermocycling program typically consisted of an initial denaturation step
at 94°C for 5 minutes, followed by another denaturation step at 94°C for 30
seconds, an annealing step at 55°C for 59 seconds, an extension step at
72°C for 30 seconds and the program wraps to the second denaturation
step for 30 more cycles after which the samples are incubated at 4°C. The
PCR products were visualized via ethidium bromide staining on a 1-2%
agarose gel.
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3.10 In Vitro Protein-Protein Interaction
3.10.1 GST-Fusion Protein Induction
A 400 mL TBA culture was inoculated with a 1:10 dilution of
overnight saturated cultures of BL21 E.coli (Pharmacia) transformed with
either pGEX-2T or the pGEX-2T recombinant fusion proteins. The
cultures were incubated for 1 hour at 37°C with nutation. Isopropyl-~-D­
thiogalactopyranoside (IPTG) was added to the culture to a final
concentration of 1 mM and growth continued at 37°C with nutation for 4
hours.
For fusion protein recovery, bacterial cell cultures were pelleted by
centrifugation at 5000 * g for 10 min at 4°C and a portion of the pellet was
resuspended in 1 mL RIPA buffer. The bacteria were lysed on ice by
sonication and centrifuged at 10 000 * g for 5 min at 4°C. The aliquots
were incubated with 200 uL glutathione-Sepharose beads that had been
previously washed three times with NETN buffer (20 mM Tris, pHS.O, 100
mM NaCl, 1 mM EDTA, 0.5% NP-40) containing 0.5% powdered milk.
The bacterial supernatant and glutathione-Sepharose beads were
incubated for 30 min at 4°C with rocking. The glutathione-Sepharose
beads and fusion proteins were washed three times with NETN buffer.
so
3.10.2 Production of 35S-Labeled Protein Using Promega's TNT In Vitro
Transcriptionffranslation Kit™
Plasmid DNA was prepared as described in Section 3.5.3. A
solution of 25 JlL of Rabbit Reticulocyte Lysate was incubated with 1 Jlg
plasmid DNA, 1 JlL of amino acid mixture minus methionine, 2 J-lL of 355-
Methionine, 0.2 JlL RNasin, 1 J.lL T7 RNA Polymerase, 2 flL TNT buffer, up
to 50 JlL with DEPC treated H20. The mixture was incubated for 90 min at
30°C.
3.10.3 GST-Pull Down Assay
A volume of 10 JlL of the radiolabeled protein was incubated for 1
hour at 4°C with 100 J.lL of NETN washed-glutathione-Sepharose beads
and the volume was brought up to 200 flL NETN. The glutathione-
Sepharose beads were washed three times with NETN buffer and the
beads were resuspended in 75 flL SDS-PAGE sample buffer and boiled for
5 minutes. The samples were centrifuged for 5 minutes at 4°C and a
volume of 12 JlL was loaded onto a 12% SDS-PAGE gel. The gel was dried
at 80°C for 2 hours under vacuum and the gel was exposed to
autoradiography.
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4. RESULTS
4.1 "Domain Swapping" Analysis of CIEBPa and CIEBP~
4.1.1 Rationale for bZIP "Domain Swapping" Analysis of CIEBPa and
CIEBP~
Previous co-transfection analysis of the endogenous PEPCK
promoter and a plasmid coding for the C/EBPa or C/EBPP protein
indicated that, unlike C/EBPa, C/EBPP was not capable of mediating a
PKA-inducible response in HepG2 cells (Roesler, et al. 1998). However,
when a significant portion of the C terminal region of C/EBP~ was deleted
(as described in Park, et al. 1999), GAL4-C/EBPP1-108 was able to mediate
the PKA-inducible response when it was tethered to the distal sites on the
PEPCK promoter. This finding suggested that the amino acids 109-315
may contain a region that attenuates the ability of C/EBPP to mediate a
PKA-inducible response on the PEPCK promoter. Alternatively, the bZIP
domain of each isoform, though highly conserved, may exert unique
regulatory properties onto their respective transactivation domains.
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In order to evaluate the effect that the bZIP domain of C/EBPa and
C/EBPP may exert on their respective transactivation domains, the bZIP
domains of C/EBPa and C/EBPP were "swapped". Site-directed
mutagenesis was used to incorporate a Kpnl site at the site corresponding
to amino acid 255 and amino acid 252 of C/EBPa and C/EBP~,
respectively. The chimera C/EBPa~ is composed of the transactivation
domain of C/EBPa linked to the DNA binding domain of C/EBP~, while
the C/EBP~a chimera is composed of the transactivation domain of
C/EBP~ linked to the DNA. binding domain of C/EBPa (Figure 4.1A). The
proteins were expressed with a HA tag fused to its N terminus so that the
expression level of each protein could be evaluated by Western analysis
without interference from endogenous C/EBP proteins in HepG2 cells.
Western analysis was performed to verify that the proteins were
expressed at comparable levels in HepG2 cells (Figure 4.1B). The control
lane represents HepG2 cells that were transiently transfected with pMl-
HA (a vector that expresses the HA-tag). Due to the small size of the
expressed HA-tag, it was run off the gel and therefore does not appear on
the blot. As indicated in the control lane, the HA antibody did not interact
with any non-specific proteins at approximately 48 kD. Although the
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Figure 4.1: "Domain swapping" analysis of C/EBPa and C/EBPp. A)
Schematic of the HA-tagged C/EBP bZIP domain "swap" mutants. To
create the "swap" mutants, the DNA binding domain of C/EBPa and
C/EBPP proteins were"swapped" or exchanged. C/EBPap is composed of
the transactivation domain of C/EBPa fused to the DNA binding domain
of C/EBPP whereas C/EBppa is composed of the transactivation domain of
C/EBPP fused to the DNA binding domain of C/EBPa. B) Western
analysis of HA-C/EBP "swap" mutants. Transient transfection analysis
was performed as indicated in Section 3.7.2. After 48 hrs, the cells were
processed as per Section 3.7.3. Equal concentration of proteins were
loaded and electrophoresed on a 12% SDS-PAGE gel and transferred onto
a nitrocellulose membrane. The control lane represents HepG2 cells that
were transiently transfected with pM1-HA (a vector that expresses the HA
tag). The"swap" mutants were detected with an antibody against the HA
tag. The 48 kD molecular weight marker is indicated.
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molecular weight of the transactivation domains of C/EBPa and C/EBPP
are almost identical, the bZIP domain of C/EBPa is slightly longer than the
bZIP domain of C/EBPp. Therefore, C/EBPap has a slightly smaller
molecular weight than the C/EBPa wild type protein and C/EBppa has a
slightly larger molecular weight than the C/EBPP wild type protein.
Although a band is present at the approximate predicted molecular
weight in lane C/EBPP, there is also a slightly faster migrating band. The
identity of this faster migrating band is unknown but DNA sequencing
and restriction analysis of the HA-C/EBPP plasmid (and the other HA-
"swap" mutants) verified the integrity of the plasmid. It may be that the
faster migrating band represents a C/EBPP protein that has been
phosphorylated by PKA on Ser 105 and/or Ser 299. The HA-tagged C/EBP
proteins were expressed to comparable levels in HepG2 cells and the
indicated proteins migrate to the appropriate predicted molecular weight.
4.1.2 Effect of CIEBP bZIP "Domain Swapping" on its Constitutive
and PKA-Inducible Activity.
HepG2 cells were transiently transfected with expression plasmids
for the C/EBPa and C/EBPp "domain swap" mutants to study the effect
that these domains have on the PKA response in the presence of the CAT
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reporter gene, -490PCK (as depicted in Figure 2.2). In this and every
transient transfection analysis performed in this thesis, an expression
plasmid which codes for the catalytic subunit of PKA is co-expressed into
the cell line to mimic the effect in a cell whereupon cAMP has triggered
the release of the catalytic subunit of PKA from the regulatory domain.
C/EBPa and its respective "swap" mutant (C/EBPap) as well as C/EBPP
and its respective chimera (C/EBppa) showed comparable constitutive
activity, which suggests that the bZIP domain does not affect the
constitutive activity of the transactivation domain. Over-expression of
C/EBPa enhanced the PKA responsiveness of the PEPCK promoter, as did
over-expression of either of the two swapped mutants, C/EBPap and
C/EBppa (Figure 4.2). However, over-expression of C/EBPP showed little,
if any, ability to enhance the PKA responsiveness of the PEPCK promoter
over that seen in HepG2 cells where no C/EBPP protein was over-
expressed ('None' lane). Clearly the transactivation domain of C/EBPP
can mediate a strong PKA-inducible response (as shown by C/EBppa) but
the bZIP domain of C/EBPP appears to exert a negative effect on its
transactivation domain. In summary, the respective bZIP domains did
not affect either chimera's ability to mediate constitutive activity but the
86
15000
~ 10000
.-
>
.-
...
U
<
~ 5000
o
0
PKA
-
+
-
+ +
-
+ - +
• t:S
cQ. l (Q..C D- ts D-
o m D. Q. m
Z w m m I!!
...... w w0 ...... ...... (J0 0
Figure 4.2: Effect of bZIP 1/domain swapping" between C/EBPa and
C/EBP~. HepG2 cells were transiently transfected with 3.5 Jlg of -490PCK
in the absence (clear bars) and presence (solid bars) of a PKA expression
vector (1 Jlg), and 1 Jlg of each C/EBP mutant, as indicated. The control
lane represents HepG2 cells that were not transiently transfected with
C/EBP expression plasmids. The values shown are the means +/- S.E. of at
least three experiments.
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bZIP domain of C/EBPP did negatively affect the ability of C/EBPWs
transactivation domain to ll'ediate a PKA-inducible response.
4.1.3 Rationale for Leucine Zipper IJDomain Swapping" Analysis of
CIEBPa and CIEBPf3
Williams and colleagues "swapped" the C/EBPa leucine zipper
domain for the C/EBPP leucine zipper domain and vice versa to create the
chimeric proteins C/EBPapLZ and C/EBppaLZ (Figure 4.3) (Lee, et al.
1997b). They determined that expression of a liver specific P-450 gene was
up-regulated when C/EBPP, but not C/EBPa, occupied sites on its
proximal promoter in HepG2 cells. "Domain swap" experiments revealed
that the leucine zipper and the transactivation domain of C/EBPP were
absolutely re~uired to induce transcription of the P-450 gene. 1bese
chimeric C/EBP proteins were obtained from the Williams' lab and they
were tested for their ability to induce transcription on the endogenous
PEPCK promoter in HepG2 cells in the presence and absence of PKA.
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4.1.4 Effect of Leucine Zipper IIDomain Swapping" on the Activity of
CIEBPo. and CIEBPJ}.
All of the C/EBP proteins tested in this experiment were shown to
induce PEPCK promoter activity in the absence of PKA by approximately
2 fold (Figure 4.4). These data were consistent with the constitutive
activity of the wild type C/EBPa and C/EBPP proteins on the -490PCK
promoter (Roesler, et aI. 1998). C/EBPa and its chimera, C/EBPapLZ,
showed comparable PKA-inducible activity suggesting that the leucine
zipper domain does not affect the PKA-inducible activity of the protein.
Similarly, the C/EBPP protein and its chimera (C/EBppaLZ) also showed
.strong PKA-inducible activity. The leucine zipper domains of C/EBPa
and C/EBPP did not alter the ability of either C/EBPa or C/EBPP's
transactivation domain to mediate a constitutive or PKA-inducible activity
of the PEPCK promoter in HepG2 cells.
One should note that, in Figure 4.4, the C/EBPP protein mediated a
strong response to PKA on the PEPCK promoter whereas, in Figure 4.2,
C/EBPP failed to mediate a PKA-inducible response. Although the reason
for this discrepancy is not immediately obvious, the answer may lie in the
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Figure 4.3: Schematic of the C/EBP leucine zipper "swap" mutants. The DNA
binding domain of C/EBPa and C/EBP(3 proteins have been "swapped" or
exchanged. CIEBPa(3LZ is composed of the transactivation domain and the basic
region of C/EBPa fused to the leucine zipper of C/EBP(3 whereas C/EBP(3aLZ is
composed of the transactivation domain and basic region of C/EBP(3 fused to the
leucine zipper domain of C/EBPa.
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Figure 4.4: Effect of leucine zipper "domain swapping" on C/EBP a and
C/EBPP activity. HepG2 cells were transfected with 7 J.lg of -490 PCK, 500
ng of each indicated plasmid and 1 ~g of PKA expression plasmid. The
relative CAT activity was calculated as the ratio of the CAT activity
measured in the presence and absence of PKA expression vector co-
transfection and these experiments are the +/- S.E. of at least three
experiments. The control lane represents HepG2 cells that were not
transiently transfected with C/EBP expression plasmids.
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fact that two different expression vectors were used to generate these
proteins. The expression vector used to generate protein in Figure 4.2 was
driven by an RSV promoter and the C/EBPP gene was derived from the
human species. The vector used to generate protein in Figure 4.4 was
driven by a CMV promoter and the gene was derived from the mouse
model. Use of different expression vectors (with different promoters) and
genes from different animal models (with corresponding differences in the
5' untranslated region and different possible translation start site) may
alter the overall expression level or activity of a protein.
4.2 StructurelFunction Analysis of CIEBPa
4.2.1 Rationale for Site-Specific Deletion Analysis of CIEBPa
Structure/function analysis of C/EBPa by a number of different
researchers have identified regions within the transactivation domain that
mediate constitutive and PKA-inducible activity (Figure 2.3) (Nerlov and
Ziff, 1994; 1995; Friedman and McKnight, 1990; Pei and Shih, 1991;
Roesler, et al. 1998). Studies by Park, et al. (1999) indicated that residues 1-
108 of C/EBP were required to mediate the PKA-inducible activity on the
PEPCK promoter. Comparison between the PKA-responsive
transactivation domains of these two family members identified three
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conserved regions (CRs) (Figure 4.5). In the experiments described below,
the contribution of these CRs to the PKA-inducible activity of C/EBPa was
explored.
Fusion proteins composed of the GAL4 DNA binding domain
fused to C/EBPa transactivation domain or the indicated C/EBPa deletion
mutants were constructed (Figure 4.6). C/EBPa N-terminal deletion
mutants were created which sequentially deleted the first 50 amino acids,
CRl, CR2, and the amino acids between CR2 and CR3. C/EBPa internal
deletions mutants were also constructed as indicated. Because the
transactivation domain of C/EBP proteins are functionally independent
from the DNA binding domain, fusion of the GAL4 zinc finger to the N
terminus instead of the C terminus of the protein has no deleterious effect
on the activity of the transactivation domain. Therefore, expression of a
GAL4-fusion protein can determine the potential a protein has to mediate
a constitutive or hormone inducible response on a permissive promoter
without interference from the endogenous proteins expressed in the cell
line.
The GAL4 fusion protein expression levels were verified by
Western analysis using a GAL4-specific antibody (Figure 4.7). Control
lanes indicate HepG2 cells that were transiently transfected with the
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Figure 4.5: Amino acid homology between C/EBPa and C/EBP~. A
computer based multiple alignment analysis was performed on the
regions of C/EBPa and C/EBP~ previously shown to be necessary to
mediate the PKA-inducible response on the PEPCK promoter. Three
regions of homology (boxed areas) were identified and termed CRl, CR2
and CR3. The corresponding amino acid residues are numbered.
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Figure 4.6: Schematic of the GAlA-C/EBPa fusion proteins. GAlA-CIEBPa
contains the entire rat C/EBPa N terminal transactivation domain (minus the first
5 amino acids) linked to the DNA binding domain of the yeast transcription factor
GAIA. The remaining constructs have modifications to the transactivation
domain as shown but are otherwise similar to GAlA-C/EBPa. Numbers above
GAlA-C/EBPa indicate the amino acid positions on the C/EBPa transactivation
domain. The predicted molecular weight (M.W.) of each protein is indicated.
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Figure 4.7: Western analysis of GAL4-C/EBPu deletion mutants.
Transient transfection analysis was performed in HepG2 cells as indicated
in Section 3.6. After 48 hrs, a nuclear extract assay was prepared and 70
flg of each extracts was resolved on a 12% SDS-PAGE gel and transferred
onto a nitrocellulose membrane. The proteins were detected with an
antibody against the GAL4 DNA binding domain. Arrows indicate the
over-expressed GAL4-fusion proteins and molecular weight markers are
shown.
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plasmid pMl which expressed the GAL4 domain. In order to achieve
sufficient separation of the protein bands, the GAL4-domain was run off
the gel and thus did not show up in the controls lanes. Several non-
specific bands were identified by comparison with the control lanes.
Identity of over-expressed proteins over non-specific bands was achieved
by examining the intensity of the bands compared to control lanes.
Although all the proteins were over-expressed, the intensity of each band
did vary slightly. For instance, the intensity of the GAL4-a~CRl band is
only approximately 2 times brighter than the non-specific band of
approximately similar molecular weight in the adjacent GAL4-a96-217
lane. Although GAL4-a~CR3 and GAL4a72-217 proteins did migrate to
the appropriate approximate position on the gel, these two proteins did
migrate to a slightly higher position than predicted. However, the
remaining GAL4-proteins migrated to the appropriate position on the gel
relative to the molecular weight standards. Multiple restriction enzyme
diagnostics and sequencing were also performed on each plasmid
construct to verify that each gene was the correct size and nucleotide
sequence (data not shown).
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4.2.2 Effect of N Terminal Deletion Mutants on CIEBPa When it is
Tethered to Distal Sites on the PEPCK promoter
Initially, the constitutive activity of the C/EBPa N-terminal deletion
constructs were evaluated in the presence of the artificial PEPCK
promoter -109/G3Al, which consists of the five cis-elements that constitute
the CRU except that the three C/EBP binding sites were replaced with
GAL4 binding sites (Figure 4.8; Roesler et al. 1996). Deletion of the first 50
amino acids of C/EBPa's transactivation domain (GAL4-a50-217) did not
affect the conc;titutive activity (Figure 4.9), although further deletion to
residue 60, which resulted in the removal of CR1 (GAL4-a60-217),
reduced the protein ability to mediate constitutive activity by
approximately 55% relative to GAL4-C/EBPa. Deletion of the N-terminal
transactivation domain up to residues 72 or 96 (GAL4-a72-217, GAL4-a96-
217) of C/EBPa had no additional effect on the constitutive activity of the
protein (Figure 4.9).
The ability of the GAL4 fusion protein to mediate a PKA-inducible
response was evaluated using the same promoter. Although deletion of
amino acids 6-49 did not reduce the constitutive activity of C/EBP, GAL4-
a50-217 showed a reduced, yet still robust, response to PKA compared to
GAL4-C/EBPu. When the residues in GAL4-C/EBPu's transactivation
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Figure 4.8: Schematic of the artificial PEPCK promoter, -109/G3Al. This
artificial PEPCK promoter reconstitutes the CRU with the exception that
GAL4 sites replace the three C/EBP binding sites and the relative position
of AP-l has been altered.
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Figure 4.9: Effect of over-expression of C/EBPa N terminal deletion
mutants in the presence of -109/G3Al. HepG2 celb were transiently
transfected with 3.5 Jlg of -109/G3A1 in the absence (clear bars) and
presence (solid bars) of a PKA expression vector (1 flg) and 1 flg of each
GAL4-C/EBPa N terminal deletion mutant, as indicated. The control lane
represents HepG2 cells that were not over-expressed with a GAL4-
C/EBPa expression plasmid. The values shown are the means +/- S.E. of at
least three experiments.
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domain up to and including CRl (GAL-a60-2l7) or both CRl and CR2
were removed (GAL4-a72-217), an almost complete loss of constitutive
and PKA-inducible activity was observed (Figure 4.9).
4.2.3 Effect of Internal Deletion Mutations on CIEBP Activity When
Tethered to Distal Sites on the PEPCK Promoter
The next step in the analysis was to specifically remove the
conserved regions within the context of the intact transactivation domain
of C/EBPa in order to assess the effect these amino acids have on the
constitutive and PKA-inducible activities on the PEPCK promoter.
Internal deletion mutants GAL4-a~CRl, GAL4-a.~CRl,2, GAL4-a~CR2
and GAL4-a~CR3 (shown in Figure 4.6) were tested by transient
transfection analysis in HepG2 cells in the presence of the reporter
plasmid, -109/G3A1. Deletion of CR1 or CR3 did not appear to affect the
constitutive activity of the fusion protein although deletion of CR1 and
CR3 did reduce the PKA-inducible activity relative to GAL4-C/EBPa, the
mutants retained substantive, albeit lower, PKA-inducible activity (Figure
4.10). Mutants lacking CR2 (GAL4-a~CR1,2 and GAL4-a~CR2) lost all
constitutive activity as well as most of the PKA-inducible activity. (Figure
4.10).
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Figure 4.10: Effect of over-expression of internal GAL4-C/EBPa deletion
mutations in -109/G3Al. HepG2 cells were transiently transfected with
3.5 J..lg of -109/G3Al in the absence (clear bars) and presence (solid bars) of
a PKA expression vector (1 J..lg) and 1 J..lg of each GAL1-C/EBPa internal
deletion construct, as indicated. The control lanes represent cells that
have not been transfected with a GAL4-C/EBPa expression plasmid. The
values shown are the means +/- S.E. of at least three experiments.
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4.2.4 Assessment of the Ability of C/EBP Mutants to Act as Dominant
Negative Mutants
The da~a in Sections 4.2.2 and 4.2.3 indicate that CR2 is a critical
domain within C/EBPa for mediating the constitutive and PKA-inducible
activity on the artificial PEPCK promoter. It was hypothesized that over-
expression of full-length C/EBPa with a deletion in CR2 may be able to
inhibit the PKA responsiveness of the PEPCK promoter due to a
dominant-negative type of mechanism. HepG2 cells are an appropriate
cell line in which to test this hypothesis since these cells have relatively
low level of C/EBPa expression compared to primary hepatocytes which
should enhance the dominant negative action of the over-expressed
mutants (Friedman et aI., 1989). Figure 4.11A depit:ts the full-length
C/EBPa and the corresponding deletion mutants ligated in-frame to a HA
tag (Charest, et aI., 1995).
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Figure 4.11: HA-C/EBPa Deletion Mutants A) Schematic of HA-C/EBPa
deletion proteins. HA-C/EBPa contains the entire rat C/EBPa N terminal
transactivation domain (minus the first 5 amino acids) linked to its
endogenous DNA binding domain and it is covalently attached to two HA
tags at its N terminus. The remaining mutants depicted have
modifications to the transactivation domain as shown but are otherwise
similar to HA-C/EBPa. Predicted molecular weight (M.W.) of each
protein is indicated. B) Western analysis of HA-C/EBPa mutants.
Transient transfection analysis was performed on HepG2 cells as
indicated in Section 3.7.2. After 48 hrs, the cells were processed as
indicated in Section 3.6. Equal concentrations of protein were loaded and
electrophoresed on a 12% SDS-PAGE gel and transferred onto a
nitrocellulose membrane. The deletion mutants were detected with an
antibody against the HA tag. The molecular weight markers are
indicated.
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Western analysis, using an HA-specific antibody, was performed to
verify that the proteins were expressed to comparable levels in HepG2
cells (Figure 4.11B). The control lane represents HepG2 cells that were
transiently transfected with pMI-HA, a vector that will express the HA
tag alone. Due to the difference in size between the expressed HA-tag and
the HA-tagged C/EBP proteins, the HA tag was run off the gel. As
indicated in the control lane, the HA antibody did not interact with any
non-specific proteins. The HA-tagged C/EBP proteins were expressed to
comparable levels in HepG2 cells (with the exclusion of HA-a~CR2) and
the indicated proteins are the correct molecular weight. Other
experiments have shown that HA-a~CR2 is expressed to levels
comparable to the other HA-tagged proteins. HA-a~CR1,2 was not
represented.
The activity of the PEPCK promoter (-490PCK) was induced by
over-expression of PKA or HA-C/EBPa, and simultaneous over-
expression ot both proteins resulted in synergistic response (Figure 4.12).
In Figure 4.12, all of the HA-tagged C/EBPa mutants had little, if any,
constitutive activity but only HA-a~CR1, HAa~CR1,2 and HAa~-CR2·
showed a reduction in PKA-inducible activity below that of the reporter
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Figure 4.12: Effect of over-expression of C/EBPa mutants on the PKA-
responsiveness of the PEPCK promoter. The reporter plasmid -490PCK
(3.5 Ilg) was co-transfected into HepG2 cells in the absence (white bars)
and presence (solid bars) of a PKA expression plasmid (1 Ilg) and 1 Ilg of
each HA-tagged C/EBPa deletion construct. The control lane represents
HepG2 cells that have not been transfected with a GAL4-C/EBPa
expression plasmid. The values shown are the means +/- S.E. of at least
three experiments.
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gene alone. These data suggest that C/EBPa mutants which lack CR1 or
CR2, inhibit the PKA-inducible activity of the reporter gene in a dominant
negative fashion.
4.2.5 Effect of Constitutive and PKA-Inducible Activity of CIEBPa
Deletion Mutants on the Glycoprotein a Subunit Promoter
The specificity of the dominant negative action of HA-a~CR1 and
HA-a~CR2 were assessed by examining the effects of these proteins on
the activity of the Glycoprotein a-subunit promoter. This promoter was
selected because it is highly responsive to PKA and this responsiveness is
mediated solely by two CREB proteins bound to two tandem consensus
CRE sites (Silver et al. 1987). Moreover, C/EBPa does not bind well to
these particular CREs (Roesler et al., 1996). As shown in Figure 4.13, none
of the indicated HA-C/EBFa proteins affected the constitutive activity or
the PKA responsiveness of this promoter. These data suggest that the
effect of C/EBPa deletion mutants is specific.
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Figure 4.13: Effect of over-expression of C/EBPa mutants on the
Glycoprotein a subunit promoter. The Glycoprotein a subunit-CAT
promoter (3.5 J,1g) was cotransfected into HepG2 cells in the absence (solid
bars) and presence (hatched bars) of a PKA expression plasmid (1 f.lg) and
1 f.lg of each HA-tagged C/EBPa deletion construct. The values shown are
the means +/- S.E. of at least three experiments.
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4.2.6 Effect of Promoter Environment on C/EBPa Activity
It is well documented that promoter environment can modify the
precise activity that transcription factors exhibit (Fry and Farnham, 1999).
The promoter used to assess the constitutive and PKA-inducible activities
of the GAL4-C/EBPa. mutants in Figures 4.9 and 4.10 had, in addition to
GAL4 binding sites, an AP-1 binding site and a CRE, as these sites
comprise parts of the CRU. To examine the influence that these sites
might have on the activity of the GAL4 fusion proteins, the activities of
the GAL4-C/EBPa. mutants were tested on a promoter containing the first
68 bp of the PEPCK promoter (which contains only a TATA box) to which
were linked four tandem GAL4 binding sites, termed -68GAL4*4 (Figure
4.14). The results shown in Figure 4.15 indicate that all of the mutants,
with the exception of GAL4-a.~CR1,2, had decreased constitutive activity
compared to GAL4-C/EBPa.. Comparison of the deletion mutant data in
Figure 4.15 (relative to GAL4-C/EBPa) with the deletion mutant data
obtained in Figures 4.9 and 4.10 (relative to GAL4-C/EBPa) clearly
indicate that the constitutive activity of the GAL4-C/EBPa fusion proteins
was significantly modified by the promoter environment in which the
mutants are assessed. For example, in Figure 4.10, GAL4-a~CR1 and
GAL4-a~CR3,which lack CR1 and CR3, respectively, had constitutive
109
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Figure 4.14: Schematic of the promoter, -68GAL4*4. The promoter -
68GAL4*4 is composed of the first 68 bp of the PEPCK promoter, a
minimal promoter consisting of a TATA box upstream of a CAT reporter
gene, to which four tandem GAU binding sites are ligated.
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Figure 4.15: Constitutive activity of the GAL4-C/EBPa mutant proteins
on -68GAL4*4. HepG2 cells were transiently co-transfe!:ted with 3.5 Jlg of
-68GAL4*4 and 1 Ilg of each GAL4-C/EBPa fusion construct. Control
lanes indicate HepG2 cells that have not been over-expressed with C/EBP
expression plasmids. The values shown are the means +/- S.E. of at least
three experiments.
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activity comparable to GAL4-C/EBPa, yet in Figure 4.15, GAL4-ahCR1
and GAL4-a~CR3 had little constitutive activity compared to Ga14-
C/EBPa. Also, in Figure 4.10, GAL4-a~CR1,2 had poor constitutive
activity compared to GAL4-C/EBPa but, in Figure 4.15, GAL4-a~CR1,2
had constitutive activity comparable to GAL4-C/EBPa. In summary, the
relative importance of specific domains within C/EBPa may vary
depending on the nature of the promoter being studied.
4.2.7 Effect of Deletion Mutants on ClEBPa Activity When They are
Tethered to PEPCK's CRE site
Based cn the findings that promoter context may play an important
role in determining the relative importance of specific domains within
C/EBPa, it was speculated that the domains within C/EBPa that mediate
the PKA-inducible response when it is bound to the sites within the LSR
may be different when C/EBPa was tethered to the CRE. It is important to
remember that although C/EBPa can occupy three sites within the LSR, it
can also bind to the CRE site on the PEPCK promoter with affinity similar
to that of CREB and C/EBPa has been shown to be able to fundamentally
replace CREB at the CRE (Roesler, et al., 1998). To test this hypothesis,
transient transfection of the GAL4-linked C/EBPa wild type and deletion
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mutants was performed in HepG2 cells using the artificial promoter
G4PEPCK (Figure 4.16). This promoter is identical to the endogenous
-490PCK vector except that the region corresponding to the CRE is
replaced with a GAL4 site (Quinn, 1993). As shown in Figure 4.17, GAL4-
C/EBPa, GAL4-adCR1 and GAL4-adCR2 mutants could mediate
comparable constitutive activity. However, GAL4-a50-217 and GAL4-
adCR3 mutants mediated a much poorer constitutive response compared
to GAL4-C/EBPa. Similar results were observed for the effect these
mutants had on the PKA-inducible activity when they were bound to the
region corresponding to the CRE. GAL4-adCR1 and GAL4-adCR2
mutants could mediate a PKA-inducible response, albeit a lower response
than that of GAL4-C/EBPa. However, GAL4-a50-217 and GAL4-adCR3
mutants mediated very little PKA-inducible activity compared to GAL4-
C/EBPa when the proteins bound to the CRE. These data indicate that
although CR1 and CR2 were absolutely required for C/EBPa to mediate
the constitutive and PKA-inducible activities when it bound sites within
the LSR (Figure 4.10), these same domains were not critical for the protein
to mediate the PKA response when it was bound to the CRE. However,
although GAL4-a50-217 and GAL4-adCR3 mediated a poor constitutive
113
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Figure 4.16: Schematic of the artificial PEPCK promoter, G4PEPCK.
G4PEPCK consists of the native -490PCK promoter with the CRE site
replaced with a GAL4 binding site.
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Figure 4.17: CR3 and the first 50 amino acids of C/EBPa mediate the
PKA-inducible response when it binds to the CRE site on the PEPCK
promoter. HepG2 cells were transiently transfected with 3.5 flg of the
artificial reporter plasmid G4PEPCK in the absence (clear bars) and
presence (solid bars) of 1 flg of the catalytic subunit of PKA and 1 flg of the
GAL4-C/EBPa deletion constructs. Control lanes indicate HepG2 cells
that were not transfected with GAL4-C/EBP expression plasmids. The
values shown are the means +/- S.E. of at least three experiments.
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and PKA-inducible activity when tethered to the CRE site (Figure 4.17),
Figure 4.10 indicated that these regions were not critical to mediate the
constitutive or PKA-inducible activity of the PEPCK gene when C/EBPa
bound to the LSR. Together, these data indicate that not only can a
transcription factor occupy multiple and variable sites on a promoter, but
also that the site where a transcription factor binds to a promoter may
dictate which domain(s) of the protein are used to mediate the constitutive
and hormone-inducible response.
4.3 Characterization of Conserved Regions 1 and 2 in CIEBPP
4.3.1 Rationale for Site-specific Deletion Analysis of CIEBPj3
The next step in this analysis was to study the CRs within C/EBP~
to determine if they contribute to the constitutive or PKA-inducible
responsiveness on the PEPCK promoter. Because CR3 is much less
homologous than CR1 and CR2, only the latter were characterized in the
C/EBPP transcription factor. Figure 4.18A shows a schematic of the GAL4-
C/EBPP constructs. The regions corresponding to CR 1 and 2 of the
C/EBPP gene were independently excised from the parent construct and
replaced with an oligonucleotide. Each oligonucleotide was designed so
that, upon translation, the endogenous amino acids would be replaced
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with alanines, ultimately disrupting the activity of the conserved region
without altering the length of the protein.
The GAL4 fusion protein expression levels were verified by
Western analysis using a GAL4-specific antibody (Figure 4.18). Control
lanes indicate HepG2 cells that were transiently transfected with the
plasmid pMl which expressed the GAL4 domain alone. Several non-
specific bands were identified by comparison with the control lanes. In
order to achieve sufficient separation of the protein bands, the GAL4-
domain was run off the gel and thus did not show up in the controls lanes.
GAL4-C/EBPP (and the chimeras) were expressed to comparable levels in
the HepG2 cells and they migrated to the predicted molecular weight.
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Figure 4.18: Schematic and expression analysis of GAL4-C/EBPP
chimeras A) Schematic of the GAL4-C/EBPP fusion proteins. GAL4-
C/EBPP contains the rat C/EBPP N terminal transactivation domain
(amino acids 1-108) linked to the DNA binding domain of the yeast
transcription factor, GAL4. The remaining constructs depicted have
modifications to the transactivation domain as shown but are otherwise
similar to GAL4-C/EBPp. B) Western analysis of GAL4-C/EBPP deletion
mutants. Transient transfection analysis was performed on HepG2 cells
as indicated in Section 3.7.2 and the cells were processed as specified in
Section 3.6. Equal concentration of proteins were electrophoresed on a
12% SDS-PAGE gel and transferred onto a nitrocellulose membrane. The
mutants were detected with an antibody against the GAL4 DNA binding
domain. Molecular weight markers are indicated.
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4.3.2 Effects of Promoter Environment on CIEBP(3 Mutant Construct
Activity
The GAL4-C/EBP~mutants were assessed for their constitutive and
PKA-inducible activities in the presence of the permissive promoters
G4PEPCK, -109G3/A1 and -68GAL4*4 (Figure 4.19). Unlike the C/EBPa
CR mutants, mutation of CR1 and CR2 of C/EBP~ did not appear to affect
the PKA-inducible response on any of the three PEPCK promoters. The
constitutive activity of the CR2 mutant was reduced when tested on the -
68GAL4*4 promoter but the activity of the mutant was strong relative to
GAL4-C/EBP~ when expressed in the presence of the other two
promoters. These data indicate that the CR1 and CR2 in C/EBP~ are not
independently responsible for mediating the constitutive or PKA-
inducible activity regardless of which cis-elements C/EBP~ occupied on
the PEPCK promoter.
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Figure 4.19: The conserved regions in CJEBP~ do not mediate PKA-
inducible activity. HepG2 cells were transiently transfected with 3.5 Ilg of
each respective promoter in the absence (clear bars) and presence (hatched
bars) of a PKA expression vector (1 tJ.g) and 1 tJ.g of each GAL4-C/EBP~
mutant construct, as indicated. The control lanes indicate HepG2 cells
that have not been transfected with GAL4-expression plasmids. The
values shown are the means +/- S.E. of at least three experiments.
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4.4 Protein-Protein Interaction Between CIEBPa and TBP and TFIIB
4.4.1 Ration~le for Investigating a Physical Interaction Between
C/EBPa chimeras and GST-TBP and GST-TFIIB
Nerlov and Ziff (1995) identified regions within C/EBPa that were
critical for mediating constitutive activity. They also performed GST-pull
down assays that indicated that amino acids 1-96 were responsible for
mediating an interaction with TBP and TFIIB, members of the general
transcription apparatus. Nerlov and Ziff further refined the region of the
C/EBPa transactivation domain that is necessary to mediate the
constitutive activity by selective amino acid mutation analysis. They
created a C/EBPa mutant with a triple mutation (amino acids 67, 77 and
78 were converted from tyrosine, phenylalanine and leucine, respectively,
to alanines) and studied this triple mutant (C/EBPa TM) in HepG2 cell
transient transfection analysis (Nerlov and Ziff, 1995). Construction of
C/EBPa TM resulted in a mutant that failed to mediate a constitutive
response. These results were substantiated by Roesler, et al. (1998) who
showed that C/EBPa TM failed to mediate a constitutive response yet it
was able to mediate a substantive PKA-inducible response on the PEPCK
promoter. The C/EBPa deletion mutants described in this thesis and the
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C/EBPa TM were in vitro transcribed and translated to determine if these
chimeras could physically interact with GST-TBP and/or GST-TFIIB.
4.4.2 GST-Pull Down Assay With CIEBPa chimeras and GST-TBP and
GST-TFIIB
The INPUT panel indicates each 35S-labeled protein was expressed
using a coupled in vitro transcription/translation kit. The darkest band in
each input lane represents the slowest migrating protein and these
proteins reside at a position on the gel that accurately reflects its predicted
molecular weight. Faster migrating proteins in each lane may represent
incomplete translation products and or proteins that have been translated
from an alternate AUG initiation codon.
GST pull-down analysis indicated that radiolabeled 355-C/EBPa
physically interacted with both G5T-TBP and G5T-TFIIB (Figure 4.20).
Removal of the first 50 amino acids (355-0.50-217) or deletion of CR3 (355-
a.8CR3) resulted in a protein that failed to interact with G5T-TBP or G5T-
TFIIB. However, 355-a.8CR1 and 35S-a8CR2 did retain the ability to
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Figure 4.20: CR3 and the first 50 amino acids of C/EBPa are required to
physically interact with GST-TBP and GST-TFIIB. GST-tag panels: A
volume of 8 ~L of 35S-labeled C/EBPa chimeras (expressed using
Promega's TNT Transcription/Translation kit) were introduced to 10 ~g of
GST-fusion proteins or GST alone bound to 100 ~L of glutathione-
Sepharose. INPUT panel: 20°1<, of the radiolabeled protein incubated with
the GST proteins were loaded into a 12 % SDS-PAGE gel. The bands were
detected by autoradiography. Molecular weight markers are indicated.
The predicted M.W. of each proteins area as follows: 35S-C/EBPa = 42 kDa;
35S-a 50-217=36.5 kDa; 35S-a~CR1=41 kDa; 35S-a~CR2=41 kDa; 35S-a~CR3=
38 kDa; 35S-C/EBPa TM= 42 kDa.
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interact with TFIIB and TBP (Figure 4.20). The ability of the C/EBPa TM
to interact with TBP and TFIIB was surprising given that transient
transfection analysis showed C/EBPa TM failed to mediate constitutive
activity on the PEPCK promoter (Nerlov and Ziff, 1995; Roesler, et ale
1998). None of the 35S-labeled mutant C/EBPa proteins interacted with
GST, as indicated by the absence of bands in the GST pCL"'lel.
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5. DISCUSSION
5.1 Role of Conserved Regions Within CIEBPa in Mediating the
Constitutive and PKA-Inducible Response on the Hepatic PEPCK
Promoter
Structure/function analyses of C/EBPa and C/EBPf3 have indicated
that their constitutive transactivation domain(s) reside within the N-
terminal portion of the protein, while the DNA-binding motif contributes
little if any to the constitutive transactivation function of the protein
(Friedman and McKnight, 1990; Nerlov and Ziff, 1994; Pei and Shih, 1991;
Roesler, et al., 1996). Previous studies have also indicated that the PKA-
inducible domain of C/EBPa resides within residues 50-124 (Roesler et al.,
1998), while the PKA-inducible activity of C/EBPP is mediated by residues
1-108, although residues 1-66 show significant activity (Park et al., 1999).
The data in this thesis indicate that CR2 plays a critical role in mediating
the PKA-inducible activity of C/EBPa when it occupies sites
corresponding to the LSR. This conclusion is supported by the
observations that (1) a GAL4-CIEBPa fusion protein containing residues
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50-217 retained PKA-inducible activity whereas a fusion protein
containing residues 60-217, which lacks CRI and CR2, lost this activity
(Figure 4.9), (2) a GAL4-C/EBPa fusion protein containing an internal
deletion of CR2 was unable to mediate the PKA responsiveness when it
was tethered to the distal sites on the promoter (Figure 4.10), and (3) the
loss of PKA-inducible activity due to the CR2 deletion does not appear to
be simply a consequence of a generalized loss of activity, since this mutant
retains the ability to confer a significant level of constitutive expression
(Figures 4.15). Because CR2 appears to be critical for mediating C/EBPa's
PKA-inducible activity when the protein binds to the distal CRU sites on
the PEPCK promoter, over-expression of a full-length version of C/EBPa
with a deletion in CR2 was evaluated to determine if this mutant inhibits
the PKA responsiveness of the PEPCK promoter due to a dominant-
negative type of mechanism. Figure 4.12 shows that the PEPCK promoter
(-490PCK) is robustly responsive to over-expression of PKA or HA-
C/EBPa, and simultaneous over-expression of both resulted in a
synergistic response. A substantial loss of PKA responsiveness was
observed in the presence of HA-aACRl,2 and HA-aACR2 (Figure 4.12)
which suggests that these mutants are acting in a dominant negative
fashion.
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The effects of the other GAL4-mutants indicate that GAL4-a50-217,
GAL4-a~CRl and GAL4-a~CR3 proteins mediate a PKA-inducible
response that was approximately 50% of that seen with the full length
C/EBPa transactivation domain (Figure 4.9, Figure 4.10). While one could
argue that these deletions might cause non-specific tertiary structure
alterations in the protein, the observation that the specified mutants
retained significant constitutive transactivation activity (Figure 4.9, Figure
4.10) indicated that no gross structural changes occurred as a result of
these mutations. Over-expression of HA-a50-217, HA-a~CR1 and HA-
a~CR3 deletion mutants resulted in little constitutive activation of the
PEPCK promoter although HA-a50-217 and HA-a~CR3 did mediate
PKA-inducible activity to levels comparable to the wild type protein
(Figure 4.12). Like HA-a~CR2, HA-a~CR1 inhibited the PKA-inducible
activity of PEPCK in a dominant negative fashion. Although other
regions within C/EBPa contribute to the PKA-inducible response on the
PEPCK promoter, only CR2 appears to be absolutely required to mediate
this PKA-inducible effect.
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5.1.1 The Constitutive and PKA-Inducible Domains of CIEBPa Are
Distinct But They May Over-Lap to a Degree
Several pieces of evidence suggest that the mechanism(s) whereby
C/EBPa mediates constitutive transactivation and PKA-inducible
transactivation are different, and involve distinct albeit overlapping
domains and/or amino acid residues. First, a GAL4-C/EBPa fusion
protein containing the entire N-terminal transactivation domain lacks any
detectable constitutive achvlty when examined in the choriocarcinoma
JEG-3 cell line, yet it nlaintains PKA-inducible activity (Roesler et al.,
1996). Second, studies with the C/EBPa TM show that this mutant fails to
mediate a constitutive response although it retains its PKA-inducible
activity. The data present in this thesis suggesting that CR2 is critical for
mediating the PKA-inducible activity when C/EBPa binds to the LSR, are
supported by the triple mutant data described above. Two of the three
mutations in C/EBPa TM (positions 77 and 78) lie outside of CR2, which
spans residues 62-70 (Figure 4.5). The third mutation in the triple mutant
(residue 67) lies within CR2. Not surprisingly, this point mutation was
shown by Nerlov and Ziff (1995) to have little independent effect on the
constitutive activity of C/EBPa, but required the additional mutations at
amino acids 77 and 78 for its effect to be noticed. Third, the C/EBPa
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deletion mutant GAL4-a~CR3 has a diminished PKA inducible activity
yet it maintains its constitutive activity when it binds to the LSR (Figure
4.10). Taken together, these data suggest that the C/EBPa domains that
mediate its constitutive and PKA-inducible activities and the mechanisms
whereby this protein medi"tes these activities are distinct, although some
amino acids/domains of the protein may participate in both responses.
5.1.2 Promoter Environment Affects Transcription Factor Activity
The data presented in this thesis suggest that promoter context may
influence the specific domain in a transcription factor that is used to
mediate transactivation. There is evidence that a transcription factor may
bind to conserved cis-elements on two promoters in a structurally distinct
manner. The pituitary gland consists of six hormone-secreting cell types,
three of which expresses the transcription factor Pit-1 which induces
expression of the growth hormone, prolactin, and thyroid stimulating
genes in somatotrope, lactotrope, and thyrotrope cell types, respectively
(Pfaffle, et al., 1996). Pit-l is a pituitary-specific, POU domain
transcription factor that activates growth hormone gene expression in
somatotropes, yet it restricts growth hormone gene expression in
lactotropes (Scully, et al., 2000). The prolactin gene promoter has a Pit-l
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site called the Prl-lP element that is conserved with the GH-l element on
the growth hormone gene promoter (Scully, et al., 2000). Therefore,
although Pit-l binds the prolactin gene promoter to induce expression,
Pit-l binds to a conserved site on the growth hormone gene promoter to
repress its expression within the same cell line. Crystallography studies
have revealed a striking structural difference in how the bipartite POU
DNA binding domain within Pit-l is accommodated on these two
promoters. The spacing between the DNA contacts made by Pit-l
changed from 4 bp upon binding to the cis-element in the Prl-1P element
to 6 bp upon binding the GH-l element (Scully, et al., 2000). Overall,
protein-DNA contacts in the major groove were generally similar between
the two complexes. The GH-l complex, however, lacked minor groove
contacts because the Pit-l terminal arm did not penetrate the minor
groove to the same extent as in the Prl-1P complex (Scully, et al., 2000).
Ultimately, Pit-l binding to the growth hormone gene promoter promoted
recruitment of a co-repressor complex whereas Pit-l binding to the
prolactin gene promoter activated gene expression in lactotropes.
The PEPCK promoter is complex; it is composed of multiple
protein binding sites to which a number of different transcription factors
can bind. Therefore, each cis-element is present within a unique
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"microenvironment" which may specifically affect the activity of a
transcription factor. Analysis of a chimeric transcription factor on a
synthetic promoter may give valuable information about the potential of a
transcription factor to mediate a constitutive or hormone inducible
response, but it does not take into account the ability of the protein to
regulate expression on a natural promoter and it may in fact lead to
misinterpretation of the role of the protein in the context of the natural
promoter (Fry and Farnham, 1999). The ability of promoter-context to
regulate transcription by modifying the precise activity of a transcription
factor may involve transcription factor-induced DNA bending,
overlapping binding sites for transcription factors, protein-protein
interactions, the structure of the core promoter, and the particular cellular
environment (Fry and Farnham, 1999). Comparison of data obtained
using -109/G3A1 (Figures 4.9 and 4.10) and -68GAL4*4 (Figure 4.15)
clearly indicate that the constitutive activity of the GAL4-C/EBPa fusion
proteins are significantly modified by promoter environment and these
data argue strongly L~at analysis of both cis-elements and the
corresponding transcription factor should be performed in the context of
the natural promoter.
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5.1.2.1 Where CIEBPa Binds to the PEPCK Promoter May Dictate Which
Domains Mediate its PKA-Inducible Response
In vitro binding assays have indicated that more than one
transcription factor can bind to most if not all of the cis-elements involved
in the PEPCK promoter CRU with similar affinity. The proteins that can
bind to the CRE include CREB (Park, et al., 1990), C/EBPa (Roesler, et al.,
1993) C/EBPB (Yamada, et aI., 1999), some ATFs (Rehfuss, et al., 1991), D-
site protein (Roesler, et al., 1992), and AP-1 related prot~ins (Gurney, et al.,
1992). C/EBPa (Park, et al., 1990), C/EBPP (Liu, et al., 1991) and D-site
binding protein (Gurney, et al., 1992) can bind to the three distal C/EBP
binding sites in the promoter, in vitro. Different levels of PKA
responsivity may be achieved with different patterns of transcription
factor binding; a mechanls~ that has been proposed to explain the
benefits of hormone response units (Roesler and Park, 1998).
When C{EBPa is functioning through the LSR on the PEPCK
promoter, CR2 is critical for mediating the PKA-inducible activity (Figure
4.10, 5.1). When binding to the LSR, GAL4-a50-217 and GAL4-aACR3 do
not appear to be critical for mediating the constitutive or PKA-inducible
activity although these mutants do mediate a reduced level of reporter
gene expression in the presence of PKA compared to the GAL4-CIEBPa.
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Figure 5.1: Schematic of conserved regions within C/EBPa protein
responsible for mediating its constitutive and PKA-inducible responses.
The numbers indicate the amino acid residues on the protein. The
domains indicating the conserved regions of C/EBPa are shaded gray; the
amino acids 1-52 are indicated as N50. The region within C/EBPa that
mediates protein-protein interactions with TATA binding protein (TBP)
and TATA binding protein associated factor II B (TFIIB) are indicated.
The basic region-leucine zipper DNA-binding motif resides at the
carboxy-terminus of the protein and does not appear to contribute to its
constitutive or PKA-inducible activity.
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However, when GAL4-C/EBPa is bound to the CRE region, removal of the
first 50 amino acids or CR3, and not CR2, greatly reduces both the
constitutive and PKA inducible activity of the protein (Figure 4.17, 5.1).
These data highlight a new level of complexity regarding the regulation of
transcription initiation. The domain within the C/EBP protein that is
responsible for mediating the constitutive or PKA responsiveness differs
depending on which cis-element(s) it occupies on the PEPCK promoter
(Figures. 4.10, 4.17, 5.1).
There are multiple cis-elements adjacent to the LSR and the CRE
that do not directly contribute to the PKA response of the promoter.
However, in the presence of PKA, distinct co-activators and/or
transcription factors may be recruited to the promoter due to the
complimentary protein contact surfaces within the enhancesome. It may
be that the conformational structure of C/EBPa is remodeled by adjacent
factors depending on which DNA element it binds and/or depending on
which proteins it interacts with on the promoter. Transcription factor
synergism may arise due to changes in each protein's ability to bind to
DNA and specific protein/protein interaction may allow the enhancesome
or a specific protein to interact with members of the general transcription
apparatus (Herschlag and Johnson, 1993). Clearly there is the opportunity
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for unique protein-protein interactions to occur between C/EBPa and
other proteins, and these interactions may cause conformational changes
that "unmask" or make more prominent a specific domain of C/EBPa that
can be used to mediate transactivation. The presentation of different
domains might, for example, result in the recruitment of different co-
activators and/or contacts with different general transcription factors that
may confer a unique transcriptional response. Nerlov and Ziff (1995)
performed GST-pull down assays with non-overlapping portions of
C/EBPa's transactivation domain and GST-TBP and GST- TFIIB. These
studies indicated that the N terminus of C/EBPa's transactivation domain
is critical for interaction with these general transcription factors. The data
in this thesis, however, indicate that although the extreme N terminus of
the transactivation domain is critical for interaction with TBP and TFIIB,
the region corresponding to CR3 is also required for interaction with these
GST-fusions (Figure 4.23). CR2, the region of C/EBPa that is critical for
mediating the PKA-inducible activity when it occupies sites on the LSR, is
not required to physically interact with TBP or TFIIB. These data may
explain the relative importance of the different domains of C/EBPa when
it binds to different sites on the PEPCK promoter (Figure 5.2). When
C/EBPa is bound to PEPCK's CRE site, the N terminal 50 amino acids and
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CR3 may mediate the constitutive and/or PKA-inducible activity by
physical interaction with members of the preinitiation complex. However,
when C/EBPu binds to the LSR, the conformational shape of the protein
may be such that these domains cannot interact with TBP or TFIIB.
Instead, the tertiary structure of C/EBPu may allow contact with co-
activators (possibly through CR2) that bridge C/EBPu to the preinitiation
complex. The domains within a transcription factor that mediate a
constitutive or hormone inducible response may be made accessible (or in-
accessible) to potential interactors depending on which cis-element it
occupies on the promoter.
5.2 Characterization of the Constitutive and PKA-Inducible Activity
of CIEBPP
It was previously thought that, unlike C/EBPu, the C/EBP~ isoform
could not mediate a PKA response and it would, in fact, inhibit the PKA
response of the PEPCK reporter gene (Roesler, et al., 1998). Park, et al.,
(1993) came to a similar conclusion when testing the effect of PKA on
activation of the PEPCK promoter in the presence of the expression
plasmids for full-length C/EBPu, C/EBPI3 and CREB. They used the CAT
reporter gene -134 PEPCK-CAT. This region of the PEPCK promoter
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contains the natural CRE site and TATA box but not the LSR. Unlike
C/EBPa or CREB, over-expression of C/EBPP in the presence of PKA did
not augment transcription of the reporter gene (Park, et al., 1993). The
data presented by Park, et al., (1999) indicated, however, that once a
significant portion of the transactivation domain and the entire bZIP
domain of C/EBPP is replaced with an exogenous DNA binding motif, this
chimera can mediate a PKA-inducible response on the PEPCK promoter
when C/EBPP1-l08 occupies the CRE (Park, et al., 1999). Two possible
conclusions from these studies could be that 1) a putative attenuation
domain resides within C/EBPP between amino acids 108 and its bZIP
domain or 2) full-length C/EBPP cannot physiologically induce
transcription of the PEPCl< gene when it is bound to the CRE unless its
activity is "unmasked" artificially or by a radical conformational change
in the protein induced by post-translational modification.
To determine whether there is a potential attenuation domain
within C/EBPP, the bZIP domains of C/EBPa and C/EBPP were exchanged
and the effect of these mutants were tested by transient transfection
analysis in HepG2 cells. Unlike C/EBPP, over-expression of wild type
C/EBPa enhanced the PKA responsiveness of the PEPCK promoter
(Figure 4.2). Over-expression of the two swapped mutants, C/EBPap and
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C/EBP~a, could mediate a significant PKA response suggesting that the
DNA binding domain of C/EBPa does not exert an inhibitory effect on the
transactivation domain of C/EBP~ nor does the DNA binding domain of
C/EBP~ negatively effect the transactivation potential of C/EBPa. It
appears that even though the bZIP domains of C/EBPa and C/EBP~ are
71% identical and 95°1<, conserved, the bZIP domain of C/EBP~ exerts a
negative effect specific to it own transactivation domain.
Lee et al., (1997b) discovered that C/EBP~ chimeras fused to the
leucine zipper domain of C/EBPa failed to induce liver specific P-450
expression. Although these two isoforms share extensive homology
.within their leucine zipper domains, they suggested that this discrepancy
in function may arise due to the ability of the C/EBP~ leucine zipper to
better dimerize with an as yet unidentified bZIP protein. While studying
the effect of these leucine zipper IIswap" chimeras on the expression of the
PEPCK reporter gene in HepG2 cells, it was identified that the
C/EBPapLZ chimera produced a transcription factor that induced the
PKA response to a greater degree than the wild type C/EBPa protein yet
the C/EBppaLZ chimera mediated a lesser PKA-inducible response than
the wild type C/EBPP protein (Figure 4.5). It is possible that the leucine
zipper domain of C/EBPP lends itself to the formation of more stable
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dimers. Therefore, although C/EBPa can mediate a stronger
transactivation potential in the presence of PKA than C/EBP~, a chimera
of C/EBPa~LZ may form more stable dimers than the C/EBPa wild type
protein resulting in a protein that can mediate a stronger PKA-inducible
response.
Although CR2 of C/EBPa appears to be critical for mediating the
PKA-inducible activity when it occupies the LSR and the first 50 amino
acids and CR3 contribute to the constitutive and PKA-inducible activity
when it binds the eRE on the PEPCK promoter, the conserved regions
within C/EBPP do not appear to contribute to the constitutive or PKA-
responsiveness on the PEPCK promoter (Figure 4.20). Although the
regions responsible for mediating C/EBPP's PKA-inducible response may
lie within the first 108 amino acids of its transactivation domain, the
variable tertiary structure of the protein may bring together distant amino
acids to comprise the PKA responsive region. Thus, although C/EBPa and
C/EBPP share some degree of homology within regions of each protein
that mediate a significant PKA-inducible response, the term "conserved
region" may not extend to a "conserved function" .
The transcription factors C/EBPa and C/EBPf31-108 are functionally
interchangeable within the GAL4 context when they occupy the LSR or
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the CRE of the PEPCK promoter (Park et al., 1999; Wilson et al., submitted)
and, in a recent review, it was suggested that, like CREB, C/EBPu and
C/EBPP have an endogenous PKA-inducible domain (Wilson and Roesler,
2002). Because a region within C/EBPP can be removed resulting in the
"restoration" of its ability to mediate a PKA-inducible response, it may be
that although this protein is capable of mediating a PKA response, this
response may not be realized by C/EBPP simply binding to the cis-
elements within PEPCK's LSR or CRE. It may be that, within the cellular
milieu, C/EBPP, unlike C/EBPu, must be phosphorylated or otherwise
modified to alter the conformational shape of its tertiary structure,
"unmasking" its PKA-inducible activity. C/EBPP can be phosphorylated
on multiple sites within its transactivation domain and DNA binding
domain by a variety of kinases including PKA and PKC (reviewed in
Roesler, 2001). For example, studies by Trautwein et al., (1994; 1995)
indicate that Ser240 of rat C/EBPP can be phosphorylated by PKA and PKC
in vitro and, upon phosphorylation, C/EBPP cannot bind DNA. However,
other studies indicate that C/EBPP is not phosphorylated by PKA to any
great extent (Wegner et al., 1992). Thus, some uncertainty remains
regarding the role of kinases in regulating the intrinsic activities of this
C/EBP isoform. It may be that one or more kinase is called upon to
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phosphorylate C/EBP~ and "unmask" the PKA-inducible activity on the
PEPCK promoter.
5.3 Recruitment of Specific CIEBP Family Members to cis-Elements
on a Promoter
When studying transcriptional activation, it is important to
consider how members of a family that share considerable homology
within their DNA binding domains, such that they display similar or
identical DNA binding specificities, can differentially regulate sets of
target genes. C/EBPa, C/EBP~ and CREB bind with near equal affinity to
the CRE site and the C/EBP isoforms bind with similar affinity to the sites
on the LSR on the PEPCK promoter (Park et aI., 1990; 1993). However,
although multiple proteins can bind to the cis-elements on the PEPCK
promoter, there may be specific recruitment of distinct proteins and/or
family members to specific cis-element on the promoter in the presence of
specific hormones. For example, because C/EBP~, and not C/EBPa nor
CREB, mediate the glucocorticoid response when it occupies the CRE site
on the PEPCK promoter, C/EBP~ may be recruited to the CRE site to the
exclusion of C/EBPa and CREB in the presence of glucocorticoids
(Yamada, et aI., 1999). DNA binding affinity may not account for the
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specific recruitment of one transcription factor over another on the PEPCK
promoter in the presence of specific hormones.
The explanation of how each transcription factor is recruited to the
promoter may lie within the creation of hormone-specific enhancesomes.
In the presence of each hormone, distinct co-activators and/or
transcription factors may be recruited to the promoter. The recruitment of
these proteins may simply arise due to the "jigsaw puzzle" concept of
complementary protein contact surfaces within the enhancesome
(McKnight, 2001). One protein or a specific protein family isoform may be
recruited to a site not due to the effects of protein kinases or DNA binding
affinities but due to the tertiary structure of the protein being able to "fit"
within the complex combination of other adjacent proteins. Evidence is
accumulating in the literature that suggests that transcription factors
synergize by aiding protein/DNA interaction or aiding in protein binding
within the enhancesome. Lee et al., (1997b) suggest that the reason why
C/EBP~,but not C/EBPu, is recruited to P-450 gene promoter is due to the
different abilities of these two proteins to interact with adjacent proteins
on the promoter. With respect to the CRU of the PEPCK promoter, the
synergism observed when all five sites of the CRU are occupied may arise
due to the combination of transcription factors allowing one or more
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inducible domains of C/EBPs lack a PKA phosphorylation site, although
C/EBPP may be phosphorylated within its bZIP domain which may in
tum affect its DNA-binding activity (reviewed in Roesler, 2001). Thus, the
mechanism whereby these domains in C/EBPs are "activated" by PKA is
unclear. There may be a co-activator that may interact with the PKA-
inducible domains of C/EBP only after itself being phosphorylated by
PKA. This scenario is suggestive of a model similar to that established for
the mechanisrl1 of CREB activation, whereby CREB is phosphorylated by
PKA which then allows recruitment of the co-activator CBP, except that
the phosphorylation of the co-activator rather than the DNA-binding
protein would regulate the interaction. Indeed, there is recent evidence
that phosphorylation of a co-activator can selectively modulate the
transcription factor with which it interacts (Yang et al., 2001). This
intrinsic activity may only manifest itself within certain promoter contexts
due to the involvement of other so-called "accessory factors". CBP/p300
mediates the PKA-inducible activity of CREB, and has been shown to be a
possible co-activator of C/EBPs (Erickson et al., 2001; Mink et al., 1997)
however, there is no direct evidence in the literature to support this
hypothesis. Since C/EBPs mediate the PKA response of the PEPCK
promoter as components of a complex CRU, it is possible that co-activator
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recruitment is achieved only by the coordinated action of several
transcription factors. This hypothesis may explain the inability to observe
some protein-protein interactions between co-activators and transcription
factors even though a functional interaction can be detected. Clearly,
identification, isolation and characterization of co-activators of C/EBPa
and C/EBPP are required in order to elucidate how these transcription
factors exert their diverse effects on gene expression.
5.5 Future Directions
The future direction of this work must determine whether C/EBPa
conforms to a specific and distinct tertiary structure depending on which
cis-element(s) it occupies on the PEPCK promoter. How C/EBPa mediates
its differential activity may not be dependent upon structure at all; it may
mediate its activity by interacting with distinct proteins within the
enhancesome. In other words, the microenvironment of the promoter
may dictate which isoform of C/EBP binds to the PEPCK promoter and/or
which domains within the protein mediate the constitutive and PKA-
inducible activity. To this end, information must be gathered about which
coactivators interact with C/EBPa when it binds to the CRE site and/or the
LSR in vivo in the presence and absence of hormones. Similarly, when
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C/EBPa binds to the LSR or the CRE, the identity of adjacent transcription
factors may help to explain why a specific isoform and/or domain of
C/EBP mediates the constitutive and PKA-inducible activity. Gaining
greater information about the microenvironment of the PEPCK promoter
and hormone specific enhancesomes may aid our overall understanding
of eukaryotic transcriptional regulation.
5.6 Concluding Remarks
The data in this thesis indicate that the relative importance of the
various conserved regions within C/EBP proteins may be dependent upon
which cis-element it occupies on the PEPCK promoter. The
"microenvironment" of each region of the promoter may dictate the
overall conformational shape of the protein. Protein binding to adjacent
sites on a gene promoter may directly or indirectly influence the binding
ability or conformational shape of a transcription factor such that the
region of the protein that is important for mediating its constitutive and/or
PKA-inducible response is influenced by where it binds to the promoter.
When C/EBPa binds to the CRE site on the PEPCK promoter, its tertiary
structure may be such that the domains that interact with TBP and TFlm
are accessible to these general transcription factors. These regions may be
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buried or otherwise inaccessible when C/EBPa binds to sites in the LSR
and, alternatively, the region of C/EBPa that interacts with a co-regulator
may be readily accessible only when C/EBPa occupies sites within the
LSR. These data highlight a new level of complexity regarding the
mechanism transcription fa~tors use to diversify hormonal responses.
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